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Abstract 
Background: 
In the UK, the prevalence of diabetes in adults in the general population is currently 
reported as just over 6% in 2014-15 [1]. This rose from a prevalence of 5.5% in 
2010. However, the most recent data from the 2016 United Kingdom National 
Diabetes In-patient Audit reported that the prevalence of diabetes amongst 
hospitalised in-patients was 17% [2]. This represented a rise of over 15% since the 
first National Diabetes In-patient Audit was carried out in 2010, and was the same 
rise in prevalence seen in the general population during that time. Thus diabetes is 
disproportionately over represented in the in-patient population.  
 
It has been recognised for many years that in-patients with diabetes experience 
‘glucose-related’ harms. Any form of dysglycaemia is associated with increased 
harms – in terms of poor outcomes (however that is defined) and also increased 
mortality [3].  
 
For many years it was well recognised that having long term high glucose 
concentrations was associated with an increased risk of developing the long term 
micro and macrovascular complications of diabetes. It was only with the publication 
of the two seminal trials, the Diabetes Control and Complications Trial in type 1 
diabetes and the United Kingdom Prospective Diabetes Study in type 2 diabetes that 
showed conclusively that in an outpatient population tight glycaemic control was 
associated with a reduced risk of developing those complications [4,5]. However, to 
date whilst there are a great deal of data to show that high glucose concentrations 
are associated with harm in hospitalised in-patients with diabetes, there are almost 
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no data to show that improving glucose concentrations is associated with benefit. 
However, most authorities agree that glucose concentrations between 6.0 and 
10.0mmol/l (with an acceptable range of 4.0 to 12.0mmol/l) are likely to be most 
beneficial (or rather, least likely to be associated with harm).  
 
In the UK there is an organisation called the Joint British Diabetes Societies for In-
patient Care group (JBDS), of which I am a senior member. JBDS is a group of 
professionals interested in the care of in-patients with diabetes. This group, which is 
funded by Diabetes UK and the Association of British Clinical Diabetologists and is a 
collaboration between these two national organisations and the National Diabetes In-
patient Specialist Nurse Group, had as it’s ‘mission statement’ the focus on 
producing evidence based or, where this was not possible, consensus based, clinical 
guidelines for the management of diabetes in hospitalised in-patients. These 
guidelines were designed to be used by non-specialists, and written in a user friendly 
way to make them clinically useful.  
 
I have been involved in writing or contributing to most of the guidelines produced by 
the group, and have been the lead author on two of the most widely read / used 
documents – peri-operative care and diabetic ketoacidosis. Indeed, as a result of my 
involvement in these writing groups, I am now recognised as an international expert 
on these two subjects. I am regularly invited to speak on these subjects, but also 
invited to write about them as well. 
 
This thesis is a journey through various aspects of my involvement in in-patient care 
for patients with diabetes from the time I was first appointed as a consultant in 
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Norwich in 2004 to the spring of 2017. In particular my hypothesis is that because of 
the work I and others have published, the management of in-patients with diabetes 
has improved the care of this vulnerable group. 
 
Methods: 
This thesis is a collection of some of the papers I have written over the last few 
years. I have divided it up into sections: admissions avoidance; general management 
of in-patients; outcomes of hyperglycaemia; diabetes in-patient treatment 
satisfaction; the management of diabetic ketoacidosis; and peri-operative diabetes 
care. 
 
Each section is written chronologically as the papers relevant to that section were 
published. I have tried to tell a ‘story’ of the development of why that particular piece 
of work was done.  
 
Part of my role as an educational supervisor is to help my junior colleagues do 
research and write this up. The papers that are written should have as part of their 
introduction a section on ‘what is known’, followed by a section on ‘what is not 
known’, with the end of the introduction being ‘what we did to fill the gap in the 
unknown’. Similarly, in this thesis, each paper has an introduction dealing with the 
background to why the paper was written and the thinking behind it. There then 
follows a section on what the study added to the literature and what changed as a 
result of the paper. Finally, there is a section on what should have been done 
differently, a reflection on the paper, and its impact and how things could and 
(maybe) should, have been done differently. The more recently published works 
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have little in the last sections because they have not had time to be widely 
disseminated or discussed, but where I have managed to reflect on the works, I have 
done so. 
 
Over the last few years, I have been part of the small team working with the Care 
Quality Commission (CQC) to ensure that diabetes care for hospital in-patients is 
now one of the very few ‘disease-specific’ areas that are included in the hospital 
inspections that they carry out. This is because of the realisation that diabetes 
patients are admitted under every speciality, that they have a complex set of unique 
needs that need to be delivered by a skilled, educated and committed workforce. 
Deficiencies in any area of care delivery will quickly show up, and the CQC has the 
power (the ‘teeth’) to ensure that hospitals deliver the standard of care that is 
necessary to prevent harm. In 2017, the CQC came up with a set of questions that 
individual Trusts must supply information on as part of their ‘pre-inspection pack’:  
 
Results: 
The work presented in this thesis shows that over the last decade or so, the care for 
in-patient diabetes has taken a greater prominence amongst diabetes professionals, 
but also at a higher level of NHS management. Inpatient diabetes has begun to take 
greater precedence within hospitals and the 2016 National Diabetes Inpatient Audit 
(NaDIA) results showed that several aspects of care had improved over the five 
years the audit had been running.  
Hospital stay: 
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The 2011 NaDIA showed that only 58% of in-patients were seen by a member of the 
diabetes team. This had risen to 69% in 2016. Unfortunately, 28% of hospitals still 
did not have in-patient diabetes specialist nurses.  
Hypoglycaemia: 
The prevalence of all hypoglycaemic episodes decreased from 26% in 2011 to 20% 
in 2016. Looking more closely, the rates of mild (self-treated) hypoglycaemia fell 
from 23% in 2011 to 18% in 2016, and the rate of severe hypoglycaemia (i.e. 
requiring third party assistance) fell from 11% to 8% between those years. Within the 
latter category, the prevalence of severe hypoglycaemia requiring injectable rescue 
treatment fell from 2.2% in 2011 to 1.7% in 2016.  
Diabetic Ketoacidosis (DKA) and Hyperosmolar Hyperglycaemia State (HHS): 
Disappointingly, in 2016 4% of in-patients with type 1 diabetes developed DKA 
during their hospital stay, a rise from 3% in 2011. The incidence of HHS in in-
patients with type 2 diabetes remained unchanged since 2015, at 0.2%.  
Intravenous insulin: 
The 2016 NaDIA data showed that there were fewer people on intravenous insulin 
infusions – 11% in 2011 and 8% in 2016. In addition, fewer people were on what was 
felt to be excessively long intravenous insulin infusions – 8% in 2011 to 6% in 2016. 
Finally, it was felt by the teams filling out the audit forms that the transfer from 
intravenous to subcutaneous insulin was better, with errors falling from 19% in 2011 
to 14% in 2016. 
Medication errors: 
Despite the increasing use of electronic prescription charts, a proportion of drug 
charts still had at least one medication error. However, the rate decreased from 40% 
in 2011 to 38% in 2016. However this still meant that almost two out of five in-patient 
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drug charts had a drug error recorded. Drug chart errors were more likely to occur for 
patients on surgical wards – 41% – compared to patients on a medical ward – 37%. 
The 2016 NaDIA data also showed that prescription errors were less likely to occur if 
in-patients were treated in a hospital that used an electronic prescription chart – 19% 
– compared to hospitals that did not use have electronic charts – 25%. The data also 
showed that the number of hospitals using fully electronic prescribing has increased 
from 16.1% in 2013, to 27.8% in 2016, with the number using partial prescribing 
falling from 12.2% in 2013, to 9.8%.  
 
In 2017, the questions that the CQC will ask individual Trusts when inspecting 
hospitals as part of their ‘pre-inspection pack’ are as follows:  
1. That the Trust participates in the annual national diabetes in-patient audit 
(NaDIA) programme 
2. That the Trust has a credible and overarching written strategy for in-patient 
diabetes care across the entire Trust as part of an approved Trust governance 
framework  
3. That the Trust has a written policy for the safe prescribing and administration 
of insulin, linked to direct or online mandatory training of all staff, with 
evidence of adoption of national guidance on in-patient diabetes care and 
insulin use, and programmes to review improvement in outcomes 
4. That the Trust has a dedicated in-patient diabetes specialist service as one of 
their core services, with routine and planned access to this service for all in-
patients with diabetes, not just emergency admissions 
5. That the Trust has a foot multidisciplinary team (MDT) for in patients with 
acute diabetic foot problems and /or high risk feet while in-patients 
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6. That the Trust has a robust system in place to identify all current in-patients 
with a known diabetes diagnosis, with evidence of a rapid referral system to 
the specialist in-patient diabetes team for those experiencing diabetes 
management problems 
 
Conclusions: 
The prevalence of diabetes continues to rise unabated, and the consequence will be 
that more people with diabetes will be admitted to hospital – for the most part not 
because of diabetes, but they will have diabetes in addition to the condition that 
necessitated admission. As I have tried to describe throughout this thesis, patients 
with diabetes in hospital unfortunately come to greater harm than those without 
diabetes. However I hope that the work that I have done, or contributed to, has in 
some way mitigated these harms. Furthermore, that unifying practice across the UK 
and elsewhere, has improved the care for people in hospital with diabetes. 
 
Guidelines in particular, can go a long way to helping standardise and improve the 
care of this vulnerable patient group, but they are not the whole answer. As these 
and other data show, there has only been partial success in their implementation and 
utilisation. Whilst a lot has been done over the last few years, there is a very long 
way to go before it can be said that the care of hospital in-patients is good and safe 
at all times. There are many areas of outstanding practice and an equally large 
number of areas where standards need to be improved.  
 
As with general diabetes care in the 1950’s onwards, we need to collect the data in a 
meaningful way that shows what outcomes are not as good as for those without 
10 | P a g e  
 
diabetes, then intervene and see if we can reduce those differences. We need to 
collect the data to show that harm is being done, before we can do something about 
it. My small contributions to the field continue because there remains a huge amount 
of work to be done. 
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Objective of this Thesis and my Hypothesis 
The objective of this thesis is to highlight some of the key peer reviewed publications 
that I have written or contributed to in the management of hospital in-patients with 
diabetes. My hypothesis is that because of the work I and others have published, the 
management of in-patients with diabetes has improved.  
 
As the prevalence of diabetes in the general population has continued to increase, 
the number of people in hospital with the condition has also risen. However, until the 
mid-2000’s the care of hospital in-patients with diabetes was not an area that had 
received much attention, nor had it been the focus of much research. In particular, 
because of the lack of awareness of the poor outcomes associated with in-patient 
hypo- or hyperglycaemia, specific care pathways or guidelines had not been 
developed, or where they had been, were often limited to use in the hospital in which 
they had been written.  
 
I have been actively involved in the care of in-patients with diabetes since I was a 
junior trainee in the mid-1990’s, but since the mid-2000’s I have published widely on 
the subject, including many national guidelines used to standardise the treatment of 
in-patients across the UK and in many parts of the world. It is possible, (although 
virtually impossible to prove), that the improved quality of care documented over the 
last few years by the National Diabetes In-patient Audit has, in part, been due to the 
work I have contributed to. 
 
  
28 | P a g e  
 
Background and Introduction 
Diabetes mellitus is a complex metabolic disorder characterised by chronic 
hyperglycaemia resulting from defects in insulin secretion or insulin action, or both. 
In 2015, the prevalence of diabetes in the UK was estimated to be in the region of 
between 4.6% and 6.0%, representing about 3.2 million people [6,7]. This is likely to 
rise over time, to an estimated 5 million by 2025 [7]. The number of people in 
hospital with diabetes is far greater than the prevalence in the general population, 
with a mean of 17%, and a range of between 4 to over 35% of hospital in-patients 
having the condition [2]. Most of the estimated 1.087million people this represents 
are admitted to hospital with their diabetes rather than because of it [8]. There is a 
systemic national issue with poor in-patient diabetes care in the UK. Work presented 
in this thesis shows that people with diabetes in hospital experience substantial 
shortfalls in the quality of care, and in-patient safety. This has been demonstrated as 
avoidable excess mortality and morbidity, and in diabetes treatment satisfaction. 
People with diabetes are more likely to be admitted; less likely to have day case 
surgery; have longer hospital stays; and experience more harms that those without 
diabetes admitted for the same conditions [9-11]. In 2013, the National Diabetes 
Information Service looked at over 10 million general hospital admissions between 
2010 and 2012. After carefully adjusting for case mix, they reported in 2013 that 
there had been an excess diabetes specific mortality of 2300 deaths during those 2 
years [12]. There are wide variations between hospitals in the UK in these outcomes, 
but the increased mortality was not due to differences in standardised mortality rates, 
suggesting this was a true excess diabetes specific rise in mortality.  
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In addition to excess mortality, the morbidity incurred by poor in-patient diabetes 
care issues incurs substantial excess treatment costs. The National Diabetes In-
patient Audit (NaDIA) is a snapshot of diabetes in hospitalised in-patients carried out 
over 1 day in individuals hospitals, during 1 particular week per year. This audit has 
taken place annually since 2011 (except 2014) and has produced a wealth of data. 
In particular, the data have shown very high rates of medication errors, errors 
associated with insulin infusion use, frequent severe in-patient hypoglycaemia, 
limited access to diabetes specialist input, poor assessment of high risk foot 
problems, and wide geographical variability [2].  
 
These shortfalls are deep rooted, systemic, and are often so large in scale that they 
have become essentially invisible to many acute hospitals. There are service models 
and interventions of proven benefit in reducing the excess morbidity and mortality 
experienced by in-patients with diabetes that are relatively simple and cost effective, 
but which many hospitals do not use. With increasing awareness of these harms that 
having diabetes presents, there has been a move in the last 10 years or so to 
address the issues that these often vulnerable patients’ experience.  
 
In the UK there has been the formation of the Joint British Diabetes Societies for In-
patient Care group (JBDS). This is a collaboration formed in 2009 of senior diabetes 
health professions made up from representatives of Diabetes UK, the main charity 
for people with diabetes in the UK; the Association of British Clinical Diabetologists 
(ABCD), the main organisation in the UK representing diabetes consultants and 
trainees; and the Diabetes In-patient Specialist Nurse group. Together this group has 
made major advances in the management of in-patients with diabetes. They have 
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produced several guidelines that are aimed at the non-specialists who treat the 
majority of patients admitted to hospital. These guidelines have been widely adopted 
or adapted across the UK and further afield. Some of these guidelines are discussed 
in this thesis. More recently, in the United States, where the health economy is more 
fragmented than in the UK, a group of endocrinologists has come together to 
address the issues as well, calling the consortium they have formed Planning 
Research in In-patient Diabetes (PRIDE) [13].  
 
This thesis is a personal journey through my own involvement with in-patient 
diabetes over the last few years. In particular, it will focus on the areas that I have 
been involved with. In each chapter I will outline the background and history of what 
had gone before, and move on to why the work presented was undertaken. After 
describing what each paper added to the literature, each presented manuscript will 
then be analysed to suggest how the care for people with diabetes in hospital has 
changed as a direct or indirect result of the work. Of course, with the benefit of 
hindsight, one would always like to have done things differently, and where this is the 
case, these will be discussed. Finally, at the end of each discussion there is a short 
section of what further work could be undertaken as a result of the paper presented. 
As stated, my hypothesis is that some of the work that I have done and contributed 
to has helped to improve that care of hospital in-patients with diabetes. 
 
As with many areas of heath care, change is a gradual process and in many 
instances the goals change as more evidence emerges. However, how the work 
presented fits into these changes will be discussed.  
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A Brief History of Treating In-patients with Diabetes  
Diabetes Related Emergencies 
Type 1 Diabetes – the Pre-Insulin Era 
Diabetes, with its symptoms of polydipsia, polyuria and loss of weight, was first 
described by Aretaeus of Cappadocia, as a ‘melting of the flesh into urine’ [14]. For 
most of human history, type 1 diabetes was universally fatal within a few months of 
initial diagnosis. One of the earliest descriptions of ‘the diabetic coma’ in the 
‘modern’ era was from 1886 [15]. In it the author – a German pathologist – described 
how, for those individuals who developed type 1 diabetes, life was miserable, and 
usually very short. It had previously been recognised that fasting (or rather, enforced 
rationing) had relieved the glycosuria of diabetes during the German siege of Paris in 
1870 and this led to the development of severe, carbohydrate free diets. By the end 
of the 19th Century several eminent diabetes specialists such as Fredrick Allen in the 
USA, or Bernard Naunyn in Germany, managed to keep people alive for a few 
months, or even a year or two on these strict, unpalatable regimens of a combination 
of alcohol, laxatives, castor oil, citrate of potassium, caffeine and other ‘circulatory 
stimulants’ [16]. All of this changed almost overnight with the discovery of insulin in 
1922 by Fred Banting and Charles Best [17].  
 
The discovery of insulin in 1922-23 was possibly the greatest medical breakthrough 
of the 20th Century. What dogged those pioneering physicians who were ‘early 
adopters’ of the new ‘wonder drug’ was how to use it – how often, how much, and so 
on, and how to balance the glucose lowering effects with the risks of going too low or 
not administering enough to prevent ketosis. It was on this background that the 
management of diabetic ketoacidosis (DKA) evolved.  
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High Dose Insulin 
An early report on the management of DKA during the first 20 years after the 
availability of insulin documented that between January 1923 and August 1940 12% 
of patients died if they presented with DKA. The report stated that they were given, 
on average, 237 units of insulin in the first 24 hours – with a mean of 83 units being 
given in the first 3 hours [18]. The author went on to report that between August 
1940 and May 1944, only 1.6% of patients died, and the average insulin dose given 
in the first 24 hours was 287 units (range 50 to 1770 units), with a mean of 216 units 
being given in the first 3 hours [18]. Thus, high dose insulin treatment for the 
management of DKA became the ‘norm’. In 1949, Black and Malins from 
Birmingham reported a case series of 170 consecutive cases of DKA treated with an 
average of 265 units (range 140 and 500 units) of intravenous insulin for those who 
were drowsy but rousable, an average of 726 units (range 250 to 1400 units) for 
those who were rousable with difficulty, and an average of 870 units (range 500 to 
1400 units) for those who were unconscious on admission [19]. What was lacking, of 
course in those very early reports was aggressive fluid management. Black and 
Malins reported that they would usually give ‘a pint [568 mls] of saline over 15 – 30 
minutes, followed by a second pint given at the same rate, and then perhaps a third, 
followed by 5% glucose given at a pint per hour’ [19]. They were, however, also 
amongst the first to describe a classification of severity for DKA, something that the 
American Diabetes Association continues to advocate [20]. 
 
Low Dose Insulin and Aggressive Fluid Replacement 
In the very early days after insulin had been discovered, it was initially in short supply 
meaning that small doses were used to treat DKA [21]. However, as insulin became 
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more widely available, the high dose regimen described previously took over as the 
accepted standard of care. Early work had showed that low dose insulin infusions 
worked as well as high dose infusions [22,23]. However, it was not until Sönksen et 
al in 1972 [24], Alberti et al in the same year [25], and subsequently Kidson et al [26] 
and Page et al [27] in back to back publications in the British Medical Journal who 
showed that low dose insulin infusions given intravenously, adequately lowered 
ketone and glucose concentrations. It was only after these publications that low dose 
regimens were put into every day practice. The doses uses were 1.2 to 9.6 units per 
hour from Kidson et al, and a fixed rate of 6 units per hour from Page et al. In 
addition, the 6 units per hour that Kidson et al administered resulted in a plasma 
insulin concentration of ~100 μU/ml. This was compared with a pancreatic output in 
a health individual of ~40 – 50 μU/ml [26]. Further work by Alberti et al [28] prompted 
Kitabchi et al and Sacks et al in the USA to undertake some of the first randomised 
trials comparing low dose vs high dose based on these data [29,30]. Further seminal 
work by Kitabchi et al established that there was no role for the routine use of 
phosphate or bicarbonate replacement in DKA [31,32]. 
 
The weight based fixed rate intravenous insulin infusion (FRIII) has also now been 
used successfully for several decades [20,33]. The concept of an FRIII is well 
established in paediatric diabetes [34], and the question often arises ‘when does a 
child become an adult’? 
 
What was still missing from the report by Kidson et al was the fluid replacement 
regimen. Page et al comment that they gave 3.66L (range 1.5 to 6L) in the first six 
hours, and a mean of 5.5L (range 2.75 to 9L) in the first 12 hours. Thus an 
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aggressive fluid regimen given together with a low dose intravenous insulin infusion 
regimen became the standard of care for the management of DKA for the next 4 
decades.  
 
Ketone and Venous Blood Gas Measurement 
In 1972 it was Hockaday and Alberti who suggested that a plasma ketone body 
concentration of greater than 3mmol/L would equate to ‘severe’ acidosis [35]. 
However, the technology needed to measure ketones meant that it was not routinely 
available. The development of urine ketone monitoring was a major advance, and 
the recommended standard of care when monitoring the treatment of DKA [36]. As 
the physiology of ketosis became better understood, it became apparent that whilst 
urine ketone sticks detected aceto-acetic acid, it was poor at detecting β-
hydroxybutyrate, the predominant ketone in the blood. With the advent of hand held 
bedside ketone monitoring equipment [37], and the better understanding that the 
pathological problem in DKA is the ketosis/acidosis rather than the hyperglycaemia 
[38], the management of DKA continued to be refined. An example of this is the 
evidence that the difference between arterial and venous pH and bicarbonate is not 
large enough to alter management and is far less invasive for the patient [39-41]. 
This has led the UK guidelines to recommend that venous blood gasses be used for 
monitoring of treatment once a diagnosis of DKA has been made [42]. 
 
Type 2 Diabetes and Hyperosmolar Hyperglycaemic Syndrome – the Pre-Medication 
Era 
What we now know as type 2 diabetes was initially described in the late 1600’s as a 
condition associated with the ‘upper classes’, and in particular to those who were 
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described as ‘corpulent’. But it was in 1886, during the Bradshawe lecture delivered 
by Dreschfeld in 1886, that he described 3 types of diabetic coma [15]. The first one 
he described as a gradual coma that is in older adults (age > 40 years) in overweight 
adults without the characteristic acetone breath or acetone in the urine. The second 
form was that of alcoholic ketosis, where nothing was noted to be abnormal about 
the breathing, but large quantities of sugar in the urine. The final form (described 
later) was that of “coma from acetonemia” [15].  
 
Subsequently increasing reports of this form of diabetic coma appeared in the 
literature [43,44]. After these cases, several authors described diabetic coma in 
which polydipsia, polyuria was accompanied by hyperglycemia but without the 
characteristic Kussmaul breathing seen in DKA [45-48]. Unlike patients with DKA, 
there were no ketones or beta-hydroxybutyrate. In addition, these patients were 
‘stout’ [15], and very physically unlike those with the characteristics of DKA, rapid 
weight loss and Kussmaul breathing with the smell of acetone on their breath [45]. 
The full extent of the metabolic derangements seen with HHS were not fully 
described till the 1950’s [49,50]. In these papers, the authors reported the severe 
hyperglycemia accompanied by osmotic diuresis but without ketonuria. They also 
suggested measurement of electrolytes such as sodium and chloride and that the 
treatment of this condition should be large quantities of fluid, with only a little insulin 
[50].  
 
It was only around that time, in about 1955, that the first oral medications became 
available to treat type 2 diabetes, the sulfonylureas. These were developed as a 
result of the profound hypoglycaemia that was noted to occur in some soldiers given 
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sulpha containing antibiotics during World War 2. The other widely used agent, 
metformin was discovered in 1922, but was only used to treat humans in 1957 [51].  
 
But despite the availability of oral agents that could treat type 2 diabetes, these 
relatively expensive drugs meant that many people remained at risk of 
hyperglycaemic emergencies. In 1971 Gerich et al [52] then Arieff and Carroll [53] 
described the diagnostic criteria for HHS and coined the term hyperglycemic 
hyperosmolar nonketotic coma (HHNK or HONK). These criteria have been 
subsequently revised and updated by the American Diabetes Association [20].  
 
In the UK DKA and HHS are considered different conditions and thus have different 
management guidelines [42,54]. In the USA, the management of DKA and HHS has 
been amalgamated into a single pathway [20]. A comparison between the 
approaches to treatment between the UK and the USA has recently been published 
[55]. 
 
The Diabetes Specialist Team 
Over the last thirty years diabetes has developed into a medical speciality in its own 
right. Many of the people who were appointed in the 1970’s and 1980’s as ‘General 
physicians with an interest in diabetes’ have now been overtaken by ‘Consultants in 
diabetes and general medicine’. This shift, whilst apparently minor, has had 
implications for the management of patients with diabetes in general, but in particular 
for those presenting with diabetes related emergencies. It was demonstrated in the 
late 1990’s that when a patient with DKA was looked after by a doctor specialising in 
diabetes, their outcomes were better than when compared to the care given by 
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‘general physicians’ [56]. With the advent of the Diabetes In-patient Specialist Nurse 
[57], there has been a wholesale move towards diabetes care being delivered by the 
specialist diabetes team. As such diabetes specialist nurses in particular provide a 
valuable service to people with diabetes and act as a vital link between hospital 
services, primary care and the patients themselves [58]. Indeed, with the recent 
implementation of the Best Practice Tariff for DKA, there is now a financial incentive 
for hospitals to provide such a service [59]. 
 
Diabetes in In-patients 
 
Those Known to Have Diabetes 
The prevalence of diabetes in the general population of Western Europe is in the 
region of 6-7%. This is expected to rise significantly over the next 20-30 years [6]. 
The prevalence in other parts of the world is much higher, in the United States the 
prevalence of diabetes is reported to be between 9.3% and 10.9% [6,60]. It has been 
recognised that having diabetes more than doubles the risk of being hospitalised for 
any given condition [9]. This is reflected in the high prevalence of diabetes in 
hospitalised patients. Data from the 2016 UK National Diabetes In-patient Audit 
(NaDIA) showed that the prevalence of hospital in-patients with diabetes ranged 
from 4% to over 35% [2]. Previous work has shown that people with diabetes have a 
longer length of hospital stay and higher mortality rates than those without the 
condition [12]. This translates to greater costs. In the UK it has been estimated that 
diabetes accounts for over 10% of the entire budget of the National Health Service, 
with the excess costs of in-patients with diabetes equating to between £573 million 
and £686 million per annum [8]. In the USA, data suggests that in 2012, 20% of the 
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health budget was spent on diabetes, equating to $245 billion, with over 40% of this 
being attributed to direct in-patient costs [61].  
 
Those Not Known to Have Diabetes 
In addition to those admissions of people who are known to have diabetes prior to 
admission, there are a number of people with hyperglycaemia who are admitted 
without a prior diagnosis of diabetes. These include those people not previously 
known to have diabetes but who continued to have it after they were discharged. 
However, some patients may develop transient hyperglycaemia (a fasting glucose 
concentration of >7.0 mmol/l, 126 mg/dl) or a random blood glucose concentration of 
>11.1 mmol/l, 200 mg/dl) during their in-patient stay which normalises after 
discharge – so called stress hyperglycaemia [62,63]. Taken together the numbers of 
people in hospital with either diabetes or transient hyperglycaemia is very large, with 
observational data reporting a prevalence of between 32% to 38% on general wards 
[64,65], and between 28 and 80% of patients with critical illness or cardiac surgery 
[65-67]. 
 
Evidence of Harm from In-Hospital Hyperglycaemia and Effect of Glucose Lowering 
Prior to the publication of large randomised control trials in the 1990s, it had been 
well recognised that poor diabetes control in ambulatory people with either Type 1 or 
Type 2 diabetes was associated with poor outcomes. It was only with the publication 
of the DCCT [4] and UKPDS [68] that it was shown that interventions to improve 
glycaemic control maintained over many years were associated with improved 
outcomes. In the world of in-patient diabetes, there is compelling evidence that high 
blood glucose concentrations are associated with a higher in-hospital morbidity and 
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mortality, prolonged length of stay, unfavourable post-discharge outcomes and 
significant excess health care costs in medical and surgical specialities [11,64,69-
71]. Umpierrez et al. showed that patients with new hyperglycaemia had a striking 
18-fold increase in in-hospital mortality, while patients with known diabetes had a 
2.7-fold increase in in-hospital mortality, when compared with normoglycaemic 
patients [64]. In 2004, a joint position statement from the American College of 
Endocrinology and the American Association of Clinical Endocrinologists on in-
patient diabetes and metabolic control concluded that hyperglycaemia in hospitalised 
patients is a common, serious and costly health care problem. There was a strong 
recommendation for early detection of hyperglycaemia and an aggressive 
management approach to improve outcomes [9]. In the UK, JBDS have produced a 
series of guidelines in managing various aspects of in-patient diabetes care, which 
also recommend aggressive glucose control [72].  
 
For surgical patients, there are data to show that hyperglycaemia in the peri -
operative period is associated with poor outcomes in several surgical specialities 
[11,71,73]. These can be measured as a variety of outcomes, such as length of 
hospital stay, development of urinary tract infections, surgical site infections, time in 
the intensive care unit, and mortality. The reasons for these adverse outcomes are 
multi-factorial, but includes failure to identify patients with diabetes and/or 
hyperglycaemia [74]; multiple co-morbidities including microvascular and 
macrovascular complications [75-78], complex polypharmacy and insulin prescribing 
errors [79]; increased perioperative and postoperative infections [11,80,81]; 
associated hypoglycaemia and hyperglycaemia [11]; lack or inadequate institutional 
guidelines for management of in-patient diabetes and/or hyperglycaemia [11,82]; and 
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inadequate knowledge of diabetes and hyperglycaemia management amongst staff 
delivering care [83]. 
 
There are also data to show that having a diagnosis of diabetes prior to having 
surgery is associated with a lowering of risk [71]. This lowering of risk is despite 
having a high glucose concentration. Thus the knowledge that a patient has diabetes 
is somehow protective. It may well be that patients with diabetes have more attention 
paid to them, and thus have more contact with nursing and medical staff. This may 
mean that post-operative problems are picked up sooner. What remains to be 
determined is whether it is the high glucose concentrations per se that causes the 
increased harm, or whether the high glucose is a marker for underlying disease 
severity. 
 
Whilst there are reasonably robust data showing that high peri-operative glucose 
concentrations are associated with harm, the data showing an association with high 
pre-operative HbA1c is currently lacking [84]. There are very few good quality 
prospective observational studies in the area of preoperative glycaemic control – as 
measured by HbA1c – as a predictive factor of postoperative morbidity and mortality. 
Recent work has suggested that risks increase when pre-operative HbA1c is greater 
than 64 mmol/mol (8%), and the UK JBDS guideline also recommends a pre-
operative concentration of less than 69 mmol/mol (8.5%) [73]. 
 
Disappointingly, to date, despite the findings that high glucose concentrations are 
associated with harm for medical and surgical patients, except for a very few clinical 
specialities such as cardiac surgery and, more recently liver transplant surgery, there 
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is yet to be any convincing evidence to show that achieving good glycaemic control 
whilst an in-patient is associated with improved outcomes [85].  
 
Variations in Care 
Over time, whilst there has been significant progress in the ‘broad brush’ of how 
diabetes should be treated in an attempt to prevent harm in the short and long term, 
what has remained is the variation in the small details on how these broad themes 
should be achieved. For example, it is accepted that lower glucose concentrations 
are associated with better long term outcomes, but how should one achieve them? 
The pharmaceutical companies develop newer agents, but the US Food and Drug 
Administration only mandates that a new product should lower HbA1c when 
compared to placebo or metformin (a surrogate maker for outcomes [86]), and that 
they do not mandate that any newer agent should be compared to other drug 
classes. Because large scale trials of new agents are expensive, (and of course 
there is the risk that doing a comparative trial may show that the competitors’ drug is 
better!), and because there is no regulatory need to conduct such trails 
pharmaceutical companies do not commonly do them. This means that when 
national and international guidelines are developed, because there are little data 
comparing drug classes directly, all of the different classes become ‘second line’ 
agents after metformin [87,88].  
 
Similarly with in-patient diabetes, currently there are a lot of data to show that 
hyperglycaemia in in-patients is associated with harm, but there are almost no data 
(other than in those undergoing cardiac surgery or liver transplant surgery) that 
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achieving glucose concentrations similar to those without dysglycaemia is associated 
with any benefit [85].  
 
On this background, there have developed differences in care pathways in how an 
outcome should be achieved. This variation is thought to be part of the reason why 
outcomes are different in different geographical locations when dealing with the 
same condition – not just in diabetes [89-91], but for a wide variety of conditions [92]. 
Variation in care was one of the factors that were found to be responsible at the 
public inquiry into the increased mortality rate found at the Mid Staffordshire NHS 
Foundation Trust (the Francis Report). They reported that “Commissioners…....must 
insist on quality and challenge the inefficiencies of providers, particularly 
unevidenced variations in clinical practice” [93]. 
 
For in-patient diabetes very little ‘formal’ data exist on variations of care. However, 
anecdotally, from my own experience as a medical registrar it was common for me 
when I moved from one hospital to the next to be asked by my consultant to ‘re-write 
the DKA guideline’. My question was always ‘Why? What is wrong with the current 
one?’ There was never a satisfactory answer and moving between several hospitals 
as part of my registrar training it became clear that whilst most of the guidelines were 
very similar (fluids, insulin, and potassium replacement), there were subtle variations 
between hospitals, often based on the consultants’ (largely non-evidence based) 
preferences. There was no data to show that the outcomes from one hospital were 
any different from the neighbouring hospitals, because a) no-one did that form of 
comparison, and b) the small differences made them difficult to compare because 
very large numbers would be needed to tease out what was better out one guideline 
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compared to any other. Thus, it was clear that harmonisation of treatment was 
needed. I believe that this is one of the reasons why the guidelines produced by the 
JBDS have been so welcomed, and so quickly adopted (or adapted) across the UK, 
and other parts of the world.  
 
There remain some differences however, across the world. In particular the 
management of DKA and HHS is subtly different in the USA compared to the UK 
[20,42,55]. However, I strongly believe that the US DKA guideline is outdated and is 
in need of revision. I believe that it should move towards the UK guideline in many 
respects – something that a senior author on the US guideline has recently 
acknowledged with me [94]. 
 
Where Are We Now? 
By the late 1990’s and early 2000’s there was a consensus to show that the best 
way to treat DKA was with aggressive fluid management and a low dose intravenous 
insulin infusion. HHS was treated differently due to the greater age, and lower 
physiological reserve of the patients, as well as the presence of co-morbidities. With 
DKA, it was agreed that regular monitoring of blood gases aided management 
decisions. For both conditions, it was also recognised that electrolyte deficiencies 
were common and that for some – potassium in particular – replacement was 
necessary. What there was no consensus about, however, was how much fluid, 
which fluid, how much insulin, in DKA, whether to use venous or arterial gases, how 
much potassium, bicarbonate yes or no, phosphate yes or no, and so on. Thus it 
was often left to individual hospitals to come up with their own DKA and HHS 
guidelines (and for the incoming registrar to rewrite them!). It was in 2006 that the 
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Association of British Clinical Diabetologists (ABCD) asked two leading clinicians to 
construct a set of guidelines that would form the basis of standardised treatment 
regimen for DKA [95]. It quickly became clear that there was an appetite for such a 
document, for use by those at the ‘front door’. However, it needed to be more 
detailed and more evidence based for emergency teams to accept its use. It was at 
this time that the Joint British Diabetes Societies In-patient Care Group was also 
formed. A collaboration between ABCD, Diabetes UK, and the National Diabetes In-
patient Nurse Group it was made of individuals interested in in-patient care. The 
authors of the initial ABCD DKA guideline were joined by others and a more 
comprehensive document was written [42], and then revised in 2013 [96]. The JBDS 
also then wrote a guideline for HHS [54]. 
 
The use of the updated DKA guideline was surveyed in 2014 and it showed that 
most hospitals in the UK use them [97,98].  
 
For DKA and HHS, there remain areas of controversy, and the guidelines are 
dynamic documents that will be updated in due course as and when new data 
become available. 
 
Much of the work in this chapter has come from two of my publications [99,100]. 
Permission to reproduce sections are shown.  
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List of Publications – to August 2017 
Many of the papers that are listed in this bibliography are not discussed in this thesis.  
Those publications that are in italics are related to in-patient diabetes care, and 
those publications which are underlined are included in this thesis. A line has been 
added to explain why the papers that are in italics have been included in this thesis.  
 
Almost none of my work on the ‘diabetic foot’ has been included in this thesis, 
because much of it is not relevant to the in-patient setting. In addition, the majority of 
the work that I did as a research fellow at the Mayo Clinic between 2001 and 2003 is 
not applicable to in-patients.  
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Title of paper: 
Gooday C, Hallam C, Sieber C, Mtariswa L, Turner J, Schelenz S, Murchison R 
Messenger G, Morrow D, Hutchinson R, Williams H, Dhatariya K (2013); An 
antibiotic formulary for a tertiary care foot clinic: admission avoidance using 
intramuscular antibiotics for borderline foot infections in people with diabetes. 
Diabetic Med 30: 581-589 
 
Impact factor of the journal 
3.12 
 
My contribution to this peer reviewed publication 
I led the group that developed the antibiotic formulary. I then had the initial idea that 
there should be an economic analysis of its use. I did the literature searches and I 
developed what factors should be included in the analysis. I analysed the results and 
I wrote the initial and final drafts of the manuscript.  
  
Background to the paper 
The diabetic foot remains the most common ‘diabetes specific’ reason for an acute 
hospital admission for people with diabetes [101]. An acute infection is the most 
commonly encountered diabetic foot problem. The most important guideline used to 
determine the management of diabetes related foot infections is that from the 
Infectious Diseases Society of America (IDSA) [102]. This guideline divides foot 
infections into ‘not infected’, ‘mild’, ‘moderate’, or ‘severe’. These categories are 
shown in shown in Table 1. Similarly, the guideline from the International Working 
Group for the Diabetic Foot (IWGDF), uses the PEDIS grade (perfusion, extent/size, 
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depth/tissue loss, infection, and sensation), with an wound classified as ‘uninfected’ 
according to the IDSA, corresponds to a PEDIS grade of 1; a mildly infected wound 
according to IDASA is a PEDIS grade 2, moderate is 3 and severely infected 
according to IDSA criteria is PEDIS grade 4 [102].  
 
Each of these categories has a suggested management plan associated with it. For 
example, the guideline says that a mildly infected wound (PEDIS grade 2) can be 
treated with narrow spectrum antibiotics according to local microbiological sample 
trends, or that people with severely infected wounds (PEDIS grade 4) should be 
admitted to hospital for treatment with appropriate intravenous antibiotics. However, 
in the moderately infected category (PEDIS grade 3), the IDSA guideline also 
advocates acute hospital admission for intravenous antibiotic treatment.  
 
As a specialist diabetic foot team we initially had no rational antibiotic policy for what 
agents to give and to whom or for how long. In addition we felt that there were a 
significant minority of individuals who fell into the IDSA category of ‘moderate’ 
infection but who were not ill enough to warrant acute hospital admission, or for 
those whom hospital admission would have an immediate serious and significant 
impact on their lives or livelihood. Thus we set out to a) rationalise our antibiotic use 
and b) to develop an admission avoidance category, by subdividing the ‘moderate’ 
category and adding a subcategory of ‘moderate infection – borderline admission’. 
This is shown in Table 2. This generated a specific diabetic foot antibiotic prescribing 
guideline shown in Table 3. This allowed consistency within the clinical team to 
ensure that whoever saw the patient would follow the same antibiotic prescribing 
rules. It also prevented potentially avoidable acute hospital admissions that, 
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according to the best known global guidelines, would have necessitated one. This 
was done by advocating the use of intramuscular antibiotics given once daily in the 
community by either the primary care nurses or by the district nurses. We then ran 
this protocol for several months and did an economic analysis of the change in 
antibiotic regimen and also of the outpatient intramuscular antibiotic regimen.  
 
Objectives of the study 
To assess the impact of empirical intramuscular antibiotic use in the treatment of 
‘severe – borderline admission’ foot infections. In particular to assess the impacts of 
admissions avoidance and any cost savings achieved. In addition, to analyse the 
outcomes and costs associated for those individuals who were treated with the 
intramuscular and oral antibiotic regimen and compared them to those who were 
admitted directly with severe infections for intravenous treatment.  
 
What this study added to the literature 
Whilst the objective of this study was not to consider rationalising an antibiotic 
protocol for the diabetic foot infections that presented to a specialist foot service, it 
was the first study to consider a specific ‘admissions avoidance’ strategy. It also 
showed that by rationalising our antibiotic prescribing we did not increase the costs. 
With respect to the intramuscular antibiotic regimen, we halved the rates of hospital 
admission for those who previously would have been admitted. Furthermore, those 
who were admitted had a significantly shorter length of hospital stay if they had had 
a course of intramuscular antibiotics prior to admission. We showed that our regimen 
led to significant cost savings.  
 
63 | P a g e  
 
 What changed as a result of the paper? 
These data are now referenced as an admission avoidance scheme in other, related, 
documents from the Joint British Diabetes Societies for In-patient Care Group [103], 
as well as by the National Institute for Health and Care Excellence [104]. As a result 
of this work, the specialist diabetes foot clinic that I lead won the ‘Admissions 
avoidance’ category in the 2012 national Quality in Care Awards, and was runner up 
in ‘Diabetes Team of the Year’ category at the 2013 BMJ awards. 
 
In 2017, the proposed update for the management of diabetic foot infections from the 
IDSA added a new category to their classification, now dividing ‘moderate’ infections 
into ‘Class A’ and Class B’. Those with ‘Class A’ infections were, like our 
classification, not unwell enough to be admitted to hospital, but had infection of 
sufficient severity to warrant parenteral antibiotics given as an outpatient [105]. 
Those with ‘Class B’ would be admitted for intravenous antibiotics. Thus our work 
has had an influence on international policy. 
 
In retrospect, what should have been done differently in this study? 
Looking back at this work, we had relatively few patients who were given 
intramuscular antibiotics, and even though we had sufficient numbers to show 
statistical significance in terms of cost savings, a larger number would have made 
the argument stronger. Prior statistical advice would have also allowed us to power 
the study more appropriately. 
 
Future work as a result of this publication 
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With the advent of a change in microbiological personnel, and an update on 
sensitivities, as well as a change in the availability of outpatient delivered 
intravenous antibiotics, our policy is currently in the process of being updated. We 
will then again look at the economic impact of this change. 
 
Confirmation of authorship 
This is shown. 
 
External link to the paper on the journal website 
http://onlinelibrary.wiley.com/doi/10.1111/dme.12074/abstract 
65 | P a g e  
 
Clinical Description IDSA 
IWGDF 
(PEDIS) 
No symptoms or signs of infection Uninfected 1 
Local infection involving only the skin and the subcutaneous tissue (without involvement of 
deeper tissues and without systemic signs as described below). If erythema, must be >0.5 cm 
to ≤2 cm around the ulcer. 
Mild 2 
Local infection (as described above) with erythema > 2 cm, or involving structures deeper than 
skin and subcutaneous tissues (e.g., abscess, osteomyelitis, septic arthritis, fasciitis), and no 
systemic inflammatory response signs (as described below) 
Moderate 3 
Local infection (as described above) with the signs of systemic inflammatory response 
syndrome (SIRS), as manifested by ≥2 of the following: 
• Temperature >38°C or <36°C 
• Heart rate >90 beats/min 
• Respiratory rate >20 breaths/min or PaCO2 <32 mm Hg 
• White blood cell count >12 000 x 106 or <4000 cells/μL or ≥10% immature (band) forms 
Severe 4 
 
Table 1 – Classification for the severity of diabetes related foot disease, taken from the Infectious Diseases Society of America 
(IDSA) and the International Working Group for the Diabetic Foot [102,106].   
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Clinical Description IDSA IWGDF 
No symptoms or signs of infection Uninfected 1 
Local infection involving only the skin and the subcutaneous tissue (without 
involvement of deeper tissues and without systemic signs as described below). If 
erythema, must be >0.5 cm to ≤2 cm around the ulcer. 
Mild 2 
Local infection (as described above) with erythema > 2 cm, or involving structures 
deeper than skin and subcutaneous tissues (e.g., abscess, osteomyelitis, septic 
arthritis, fasciitis), and no systemic inflammatory response signs (as described below) 
Moderate 3 
Cellulitis > 2 cm around the ulcer associated with lymphangitis or foot 
failing to respond to oral antibiotics alone and not systemically unwell 
Moderate infection - 
borderline admission 
Local infection (as described above) with the signs of SIRS, as manifested by ≥2 of the 
following: 
• Temperature >38°C or <36°C 
• Heart rate >90 beats/min 
• Respiratory rate >20 breaths/min or PaCO2 <32 mm Hg 
• White blood cell count >12 000 x106 or <4000 cells/μL or ≥10% immature (band) 
forms 
Severe 4 
Table 2 – Our modified severity classification, including the admissions avoidance category ‘Moderate infection – borderline 
admission’ [107]. 
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Table 3 – Award winning diabetic foot antibiotic prescribing guideline generated from our modification of the IDSA guideline [107].
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Title of paper: 
Gooday C, Murchison R, Dhatariya K (2013); An analysis of clinical activity, admission 
rates, length of hospital stay, and economic impact after a temporary loss of 50% of the 
non-operative podiatrists from a tertiary specialist foot clinic in the United Kingdom. 
Diabetic Foot & Ankle 4: 21757 
 
Impact factor of the journal 
Unavailable – not listed. However, according to Google Scholar (accessed 1st October 
2017) this paper has been cited twice. 
 
My contribution to this peer reviewed publication 
I lead the multidisciplinary foot clinic at the Norfolk and Norwich University Hospital. The 
immediate impact of the loss of the podiatrists led to me having the initial idea that there 
should be an economic analysis of their loss. I did the literature searches and I developed 
what factors should be included in the analysis. I analysed the results and I wrote the 
initial and final drafts of the manuscript.  
 
Background to the paper 
The ideal multidisciplinary foot team is made up of the podiatrists, the diabetes doctor, the 
orthopaedic and vascular surgeons, the microbiologist, radiologist, orthotist, and diabetes 
specialist nurse. In the diabetic foot clinic at the Norfolk and Norwich University Hospitals 
that I lead I am very pleased that over the 8 years that I have led the team, we have every 
one of these groups represented. At the start of the list were the podiatrists. This is 
because they do the bulk of the work and are the ‘gate keepers’ for who needs to be seen 
by the consultants, and in which speciality clinics they need to be seen in (medical, 
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vascular or orthopaedic). They also work daily on the wards, assessing new cases of 
diabetes related foot disease that have either been admitted as a result of the foot 
disease, or an individual that has been found to have a diabetes related foot problem in 
addition to the primary cause for their admission.  
 
Much of this work is done as part of their ‘day-to-day’ activity and does not generate any 
income for the acute Trust, and thus, in the past they have been deemed as an ‘expense’ 
rather than revenue generating to the teams responsible for fiscal accountability. 
 
In 2010, due to an entirely unforeseeable set of circumstances, we lost 50% of our 
specialist podiatry staff in a very short time. This led to an immediate reduction, and in 
some cases cessation, of some aspects to the service delivered by the foot clinic. This 
study was an opportunistic way of assessing the economic impact – or worth – of 
podiatrists in a specialist diabetic foot clinic. We looked at clinic activity (‘income 
generation’), as well as hospital admission rates, amputation rates, and hospital length of 
stay for patients (‘cost’) with diabetes related foot disease for the time prior to the loss of 
staff, during that time, and for the 6 months after the full complement was re-established. 
 
Objectives of the study 
To assess the economic impact of a loss of half of our specialist podiatrists by undertaking 
a formal review of our in-patient and outpatient activity before and after a 7-month 
interruption of normal service. We also compared the number of admissions due to 
diabetic foot complications and looked at the number of overall ‘bed days’, i.e. number of 
days per year that a bed at our institution was occupied by someone with a diabetic foot 
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problem. In addition, we looked at the length of stay of hospital in-patients admitted with 
foot problems before and during the period of staff shortage.  
 
What this study added to the literature 
For the first time, we were able to show that podiatrists save a lot of money. The acute 
Trust, and the Primary Care Trust did not replace the missing members of staff (other than 
occasional non-specialist podiatrists from the community) for over seven months. During 
that time length of stay went up, the number of expected amputations rose, and the delay 
in getting urgent referrals meant a larger number of ‘excess’ acute hospital admissions 
during that time. In addition, because the team had to focus on the more complex feet, 
those with less need were discharged into the community, thus generating less income as 
well as increasing costs. These data showed that the income generated went down by 
23% (£407,285 the year before the loss of staff to £214,006 for the year during which 
there was the staff absence), with an increased expenditure of almost £90,000 due to the 
factors mentioned.  
 
A full time band 7 specialist diabetes podiatrist at that time cost at that time was £35,184.  
 
 What changed as a result of the paper? 
We used this economic data to successfully argue to the Primary Care Trust and the 
Acute Trust that the short term saving they felt they had achieved by not employing 
replacement podiatrists had led to a significant escalation in overall costs within other 
parts of the hospital. This was because of the rise in admissions due to diabetes foot 
disease that could have very easily been managed in the outpatient clinic. These data 
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have been used by other Trusts across the UK to justify employing specialist podiatrists as 
part of an overall ‘admission’s avoidance’ strategy. 
 
In retrospect, what should have been done differently in this study? 
The set of circumstances that led to the halving of the numbers of podiatrists was 
unforeseeable, and unexpected. We had tried for a long time to justify why employing 
podiatry staff was economical, but without ‘proof of worth’ the funders of the service felt we 
had just been trying to promote our own service. These data show that we were not. 
However, it took us several months to go through the data to show what effect this loss of 
staff had had. If we had collected the activity, admission, amputation data etc., in real time 
as part of routine clinical work then it would have taken us less time to gather the evidence 
we needed to convince the Primary Care Trust and the Acute Trust to adequately fund the 
service, and of course fewer individuals would have lost their legs. As a result of this 
episode we now collect this data as a matter of routine. 
 
Future work as a result of this publication 
This paper represented the chance to conduct an opportunist, stand alone, piece of work. 
It was not anticipated, and thus currently no further work will need to be repeated (one 
hopes).  
 
Confirmation of authorship 
This is shown. 
 
External link to the paper on the journal website 
http://www.tandfonline.com/doi/full/10.3402/dfa.v4i0.21757   
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Title of paper: 
Daultrey H, Gooday C, Dhatariya K (2011); Increased length of in-patient stay and poor 
clinical coding: audit of patients with diabetes. J R Soc Med Sh Rep 2: 83 
 
Impact factor of the journal 
Unknown. This is currently not a ‘listed’ journal. Google Scholar reports that this paper has 
been citied sixteen times [accessed 1st October 2017] 
 
My contribution to this peer reviewed publication 
I lead the multidisciplinary foot clinic at the Norfolk and Norwich University Hospital. I had 
the initial idea to try and get our own institutions’ data on length of stay for our patients 
admitted with diabetes related foot disease. I supervised the medical student who did the 
data collection. I did the literature searches and I analysed the results and I wrote the 
initial and final drafts of the manuscript.  
 
Background to the paper 
People with diabetes have longer hospital stay than those without diabetes [10]. In 
addition, the most frequent cause of an acute diabetes specific hospital admission is the 
‘diabetic foot’ [101]. It has been well recorded that clinical coding is done poorly, with 
patients with diabetes also being affected by this [108]. 
 
Since the split in 1991 of the health service into ‘providers’ and ‘purchasers’, secondary 
care institutions need to bill primary care funders for the services they provide. The 
amount needed to bill is dependent on knowing what to bill for. There is a fixed cost 
associated with each diagnosis that a patient could have. These diagnoses and 
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associated costs are derived from Healthcare Resource Group (HRG) codes [109]. These 
HRG’s are translated by clinical coding at each hospital from the data written on the 
discharge summary from each individual patient that is sent to the general practitioner. If 
there are incorrect diagnoses, then the hospital may get paid less than it should be for the 
work that it has done. The amount received is according to the corresponding HRG code 
for that diagnosis. In addition, for every diagnosis that is not included (i.e. just the primary 
admission diagnosis is listed on the discharge summary and no other pre-existing co-
morbidities) then, again, the hospital gets paid less that it could otherwise have been.  
 
The discharge summary is thus the mechanism by which a hospital generates a lot of its 
income. However, this important document is often filled out by the most junior member of 
the medical team who often has little or no idea of the importance of the discharge 
summary – the Foundation Year doctor.  
 
This study looked at discrepancies between those people known to have diabetes related 
foot disease on a particular day in the hospital and looking at the discharge summaries 1 
year later, how often that was recorded on the discharge summary, and also whether 
length of hospital stay was longer for those known to have diabetes, compared to those 
who did not.  
 
Objectives of the study 
To establish if patients with diabetes and foot problems were in hospital for longer than the 
national average length of stay, as stated by the Hospital Episode Statistics database. 
Another objective was to identify the accuracy of clinical coding within the Norfolk and 
Norwich University Hospital (NNUH), establishing its reliability for future research. This 
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was the first such piece of work at the NNUH looking at patients with diabetes and foot 
problems.  
 
What this study added to the literature 
It confirmed what had previously been known. A) That diabetes was poorly recorded on 
the discharge summary, even when it was the primary cause for admission, and when 
having diabetes in addition to any other diagnosis increased the tariff associated with a 
hospital admission. B) That patients with diabetes stay in hospital for longer than those 
who do not have the condition 
 
 What changed as a result of the paper? 
We have tried to ensure that discharge summaries are prioritised by our junior staff. They 
are started at the time of hospital admission, and all known diagnoses are listed, not just 
the condition for which the patient was admitted.  
 
In retrospect, what should have been done differently in this study? 
This was a cross sectional study taken on 1 day only. Clearly this has some limitations, 
but is similar in nature to the data collection exercise conducted as part of the National 
Diabetes In-patient Audit [101]. To get a better idea, a longer study over time would have 
been better, and information technology systems now allow this to be done.  
 
Future work as a result of this publication 
These data need to be repeated to see if any improvements have been made, although, to 
date, this has not been done.  
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Confirmation of authorship 
This is shown. 
 
External link to the paper on the journal website 
http://journals.sagepub.com/doi/full/10.1258/shorts.2011.011100  
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Title of paper: 
Narwani V, Swafe L, Stavraka C, Dhatariya K (2014); How frequently are bedside glucose 
levels measured in hospital in-patients on glucocorticoids? Clinical Medicine 14: 327-328 
 
Impact factor of the journal 
1.63 
 
My contribution to this peer reviewed publication 
I had the initial idea to try and find out what the prevalence of glucocorticoid use was in 
hospital in-patients, and then to find out how many of them had glucose concentrations 
measured. I supervised the medical students who did the data collection. I did the 
literature searches and I analysed the results and I wrote the initial and final drafts of the 
manuscript.  
 
Background to the paper 
In November 2013 I attended the Autumn Meeting of the Association of British Clinical 
Diabetologists. At that time I was a member of the executive committee, and was the 
meetings secretary. During the event I discussed the possibility of producing a guideline 
on steroid induced hyperglycaemia with a few other attendees. This idea was warmly 
received. However because of the resistance that I had encountered when trying to 
disseminate the findings of the Joint British Diabetes Societies for In-patient Care (JBDS) 
group national guideline on the perioperative management of patients with diabetes 
undergoing surgery from the anaesthetists and surgeons, I felt that we may get a similar 
degree of resistance from those medical specialities who were high prescribers of 
glucocorticoids.  
82 | P a g e  
 
As one of the writing group of the JBDS guideline on the management of Hyperglycaemic 
Hyperosmolar Syndrome [110], and as someone who relatively frequently came across 
patients admitted with hyperglycaemia a few days after starting glucocorticoids I felt this 
was an important issue. However, I was also aware from previous conversations with 
colleagues from the gastroenterology, dermatology, rheumatology, chest and oncology 
departments, they did not feel that glucocorticoid induced hyperglycaemia was an issue. 
They all acknowledged that glucocorticoid use was associated with hyperglycaemia, but 
they did not know how often it occurred. Looking at the literature it was clear that there 
was evidence for frequent glucocorticoid use in the community [111,112]. However, what 
was not known was the prevalence of glucocorticoid use in hospital. Thus we undertook 
this point prevalence survey to see how common glucocorticoid use was at the Norfolk 
and Norwich University Hospital.  
 
Objectives of the study 
The objective was to assess the prevalence of glucocorticoid use in a large university 
teaching hospital. Furthermore, what were the indications for use and finally, to determine 
how many individuals on glucocorticoids were having regular blood glucose 
concentrations measured. We also wanted to know if blood glucose testing was more 
frequent in people with a previous diagnosis of diabetes mellitus. 
 
What this study added to the literature 
This is the first study that looked at the prevalence of glucocorticoid use in hospital in-
patients. We found that 12.8% (n=120) of all in-patients were on some form of 
glucocorticoid, but that of those, only 20.8% of these (n=25) had any evidence of blood 
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glucose testing. Of these, 13 were known to have pre-existing diabetes. Thus we showed 
that glucose testing in people in hospital receiving glucocorticoids was very poor.  
 
 What changed as a result of the paper? 
These data were included in the JBDS guideline on the management of hyperglycaemia 
and steroid (glucocorticoid) therapy that was launched in 2014 [113]. This has also fed into 
other work that I have done, but not mentioned in this thesis on the impact of giving 
dexamethasone as part of an anaesthetic regimen [114]. 
 
In retrospect, what should have been done differently in this study? 
This work was done by an enthusiastic group of medical students over a weekend. It 
would have been better to have a longer assessment period, with regular assessments of 
prevalence. In addition, it would have then been possible to see if the outcomes for people 
on glucocorticoids was different (e.g. length of hospital stay, or mortality) to those not on 
the drugs.  
 
There are further potential differences between those receiving glucocorticoids as part of 
treatment for a long term medical condition, (gastroenterological, respiratory, oncology, 
dermatological, or rheumatological), as opposed to a short (even single) dose as part of 
e.g. a peri-operative regimen. These differences would need to be explored, but as stated 
in other work I have done (that is not mentioned in this thesis), to assess the impact of 
harm associated with e.g. peri-operative dexamethasone use, the numbers needed would 
need to be very large [115]. To look at differences in peri-operative outcomes for those 
given peri-operative steroids, looking at the prevalence of diabetes in the community, the 
risk of developing post-operative hyperglycaemia with a dose of steroid, the risk of 
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developing post-operative complications as a result of that hyperglycaemia and then 
aiming for a statistically significant difference, the sample size is estimated at over 15,000 
people. This would require a multi-centre collaborative trial. 
 
Future work as a result of this publication 
This work has led to collaborations with the department of surgery and anaesthesia in 
Vanderbilt University School of Medicine in Tennessee where they have a very large 
database of over 200,000 patients who have undergone surgery, with over 75% of them 
having received glucocorticoids as part of their anaesthetic regimen. This should give us 
sufficient numbers to assess differences in outcomes between those who did receive them 
and those that did not. 
 
Confirmation of authorship 
This is shown. 
 
External link to the paper on the journal website 
http://www.clinmed.rcpjournal.org/content/14/3/327.full?sid=76515a90-721d-464f-9e2d-
a7990219baab   
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Title of paper: 
Evans NR, Dhatariya KK (2012); Assessing the relationship between admission glucose 
levels, subsequent length of hospital stay, readmission and mortality. Clin Med JRCPL 12: 
137-139 
 
Impact factor of the journal 
1.63 
 
My contribution to this peer reviewed publication 
I had the initial idea to try and find out what the relationship was between admission 
glucose concentrations and outcomes. I supervised the junior doctor who did the data 
collection. I did the literature searches and I analysed the results and I wrote the initial and 
final drafts of the manuscript.  
 
Background to the paper 
Hyperglycaemia is common in patients presenting to emergency departments. This is 
either due to the presence of pre-existing diabetes, or due to the transient hyperglycaemia 
of acute illness – ‘stress hyperglycaemia’ [63,116]. Previous work had looked at the impact 
of glucose concentrations at initial presentation, and subsequent outcomes in specific 
disease areas, e.g. pneumonia, stroke or acute coronary syndrome [117-119]. Work 
looking at ‘all comers’ had previously been done, but in the USA, which showed a 
relationship between admission blood glucose and outcomes [64]. All of these studies 
showed that high glucose concentrations on initial presentation was associated with 
poorer outcomes, using whatever measure chosen to determine ‘outcomes’, e.g. longer 
length of hospital stay, increased mortality and so forth. 
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However, because of the large differences in the way that health care provision was 
delivered in the USA, it was unclear whether those finding could be directly translated to 
the UK. On this background we undertook this study that looked at all admissions to the 
Acute Medical Unit (AMU) at the Norfolk and Norwich University Hospital for one month in 
February 2010 (n=1502) and found those who had blood glucose concentrations 
measured (n=893). We used outcome measures that had been previously published by 
others to ensure that our data were comparable. 
 
Objectives of the study 
The objective was to investigate the relationships between dysglycaemia and length of 
stay, short-term mortality and readmission in an unselected AMU population. The follow-
up rate of hyperglycaemia in individuals without diabetes was also measured.  
 
What this study added to the literature 
These data show that in an unselected UK population presenting to an AMU that high 
glucose concentrations at the time of admission were strongly correlated to increased 
length of hospital stay, increased 28 day readmission rates, and higher 28 day mortality. 
There were no differences depending on age, gender or admission speciality. These data 
were the first of their kind to show this in the UK.  
 
These data add to the wealth of evidence to suggest that glucose should be measured on 
all patients presenting to an Emergency Department  
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What changed as a result of the paper? 
Many other authors have now repeated this exercise and shown the same results. As of 
October 2017, according to Google Scholar, this paper has been cited 30 times. The 
authors of many these other papers, have used our data as a starting point from which to 
develop strategies to a) diagnose diabetes / stress hyperglycaemia at an earlier stage b) 
to develop algorithms and decision tools for use in the emergency department to reduce 
length of hospital stay [120].  
 
In retrospect, what should have been done differently in this study? 
Because we were able to show what we set out to, within a relatively short time frame, we 
were successful in our goal. In addition, these data have been the springboard for a 
number of other pieces of work that have aimed to improve the outcomes of people 
presenting to emergency departments. Thus, I feel that we did what we had to do, and I 
would do nothing different. 
 
Future work as a result of this publication 
We used the same dataset to assess if the single glucose measurement taken at the time 
of the acute hospital admission predicted outcomes at one and two years after this 
admission – this work is presented later in this thesis. 
 
In addition, these data have also been part of the more recent conversations surrounding 
the important issue of diagnosing new diabetes in adults during hospital admissions. 
Indeed there is a new guideline from the Joint British Diabetes Societies for In-patient 
Care Group dealing with this issue due for publication in Autumn 2017.  
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Confirmation of authorship 
This is shown. 
 
External link to the paper on the journal website 
 
http://www.clinmed.rcpjournal.org/content/12/2/137.full?sid=76515a90-721d-464f-9e2d-
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Title of paper: 
Haddadin F, Clark A, Evans N, Dhatariya K (2014); Admission blood glucose helps 
predict 1 year, but not 2 years, mortality in an unselected cohort of acute general medical 
admissions. Int J Clin Pract 69: 643-648 
 
Impact factor of the journal 
2.57 
 
My contribution to this peer reviewed publication 
I had the initial idea to try and find out what the long terms relationship was between 
admission glucose concentrations and 2 year outcomes. I supervised the junior doctors 
who did the data collection. I did the literature searches and I wrote the initial and final 
drafts of the manuscript.  
 
Background to the paper 
Previous work had been done elsewhere looking at the relationships of blood glucose 
concentrations at the time of hospital admission and short term outcomes in selected 
cohorts of patients [117-119]. These data showed that the higher the admission glucose 
concentration, the greater the likelihood of an adverse event – longer length of hospital 
stay, greater risk of death, etc. We had previously looked at the relationship between 28-
day outcomes in terms of length of hospital stay, readmission rates and mortality 
according to the admission blood glucose concentrations of all patients presenting to the 
Acute Medical Unit of the Norfolk and Norwich University Hospital during February 2010. 
These data have been presented earlier in this thesis. Those data showed, in agreement 
with the previous work, that high admission glucose concentrations were associated with 
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clinically significant and statistically significantly poorer outcomes when compared to those 
admitted with normal glucose values.  
 
Objectives of the study 
Using the data that we had collected from a previous study presented elsewhere in this 
thesis, we wanted to see whether that single admission glucose concentration also helped 
to predict longer term outcomes, in particular one and two year mortality. We used that 
initial cohort and then looked to see who was alive at one year and two years later, and if 
there was a correlation between risk of death and glucose concentrations on admission to 
hospital.  
 
What this study added to the literature 
This dataset was the first time that a longer term assessment of the relationship between a 
single blood glucose concentration taken at the time of an acute hospital admission and 
the relationship between that glucose and the risk of death in the next 2 years.  
 
 What changed as a result of the paper? 
As is explained in the section on the commentary piece in the British Medical Journal 
discussed later in this thesis, whilst this data adds to the wealth to show that a high 
glucose concentration during hospital admission is associated with increased risk of harm, 
there are currently no data (other than in cardiac and liver transplant surgery) to show that 
normalising glucose concentrations is associated with a reduction in that risk. Thus this 
paper adds to the information to show that the risks are not limited to the current hospital 
admission, but can help to predict future risk of premature death. 
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In retrospect, what should have been done differently in this study? 
As part of this data collect we were limited to knowing which specialist they were triaged 
to. In our institution, we have a ‘speciality triage system;’ all patients are assessed in the 
Acute Medical Unit and then triaged to the appropriate speciality. What we did not have at 
the time of writing is to see what the individuals died of, and to see if there were any 
correlations with that. It is likely however, that even with almost a thousand people, of 
whom a large proportion died, that the number of people who died from any particular 
cause of death with a particular glucose concentration would have been small to be able 
to make any clear correlations possible. Much larger numbers would have been needed.  
 
Future work as a result of this publication 
Currently, this work has fed into the work in the surgical arena. There are very similar data 
to show that in surgical admissions, high pre and post-operative glucose concentrations 
are related to an increased risk of complications and death. However, most of the data 
looking at complication rates are limited to 30 day post-operative outcomes. These data 
suggest that we should also be looking a longer timeframes. I am currently leading a 
project being planned that will involve conducting a large multicentre study see if there is a 
relationship between random glucose and HbA1c values taken at the pre-operative 
assessment clinic and 30 day outcomes. However, as part of this, it is planned to also look 
at one and two year outcomes. 
 
Confirmation of authorship 
This is shown. 
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External link to the paper on the journal website 
http://onlinelibrary.wiley.com/doi/10.1111/ijcp.12574/full   
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Title of paper: 
Dhatariya K (2013); Should in-patient hyperglycaemia be treated? Br Med J 346: f134 
 
Impact factor of the journal 
19.97 
 
Background to the paper 
As one of the senior members of the steering group of the Joint British Diabetes Societies 
for In-patient Care Group, and as one of the senior co-authors, or lead authors on most of 
the guidelines that the group has produced I had read a lot of material on the impact of 
high glucose concentration in hospital in-patients. These data are best summarised by the 
statement that “high glucose concentrations in hospitalised in-patients significantly 
increases their risk of harm – however that harm may be defined”. In many respects this is 
the same situation as general outpatient diabetes care was up to the early 1990’s – that 
“high glucose concentrations over a period of many years in people with diabetes 
significantly increases the risk of micro and macrovascular complications”. It was only with 
the publication of the two seminal intervention trials in diabetes – the Diabetes Control and 
Complications Trial (DCCT) for people with type 1 diabetes [4], and the United Kingdom 
Prospective Diabetes Study (UKPDS) [5,68] that it became clearer that lowering glucose 
concentrations reduced the risk of developing complications. In the world of in-patient 
diabetes, as mentioned, we have a lot of data to show that high glucose concentrations 
are associated with harm, but as yet, we have very little data to show that intervention 
makes a difference in reducing that harm. This ‘uncertainties’ page in the BMJ outlines this 
point. That whilst there are very good theoretical arguments for lowering blood glucose 
concentrations, there are almost no data (other than in cardiac or liver transplant surgery) 
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to show that these interventions make any difference to outcomes, other than by 
increasing the risk of harm due to severe hypoglycaemia. 
 
Objectives of this peer reviewed paper 
I wanted to summarise the data that had been published to date. In particular to state that 
whilst there was a great deal of evidence to show that hyperglycaemia in hospital in-
patients was associated with harm, and poorer outcomes, there was very little consistent 
data (except, possibly in cardiac and liver transplant surgery) to show that intervening, and 
lowering glucose concentrations made a difference. Thus, to practice ‘evidence based 
medicine’, when there is no evidence of benefit, I questioned should it be done? 
 
What this study added to the literature 
This commentary put into words one of the great fears that I had been having over the 
time that I have been a senior member of the Joint British Diabetes Societies for In-patient 
Care Group. Almost all of the guidelines advocate aiming for an ideal glucose 
concentration of 6.0 to 10.0mmol/L, with a range of 4.0 to 12.0mmol/L being acceptable. 
However, these targets have all been consensus based, with no evidence at all for these 
recommendations. In addition, for many people, achieving these targets in hospital would 
require being on insulin, a drug known to be one of the most frequent causes of severe 
harm in hospitalised patients [79,121,122]. It enunciated the argument between being 
seen to address a recognised problem, but without any evidence to justify the actions we 
were promoting. If one were a ‘purist’ who followed only evidence based medicine, then 
given there is no evidence of benefit, should hyperglycaemia in hospitalised in-patients be 
treated? However, with the lack of evidence that treating high glucose concentrations is 
associated with benefit, but is very definitely associated with an increased risk of harm 
99 | P a g e  
 
from hypoglycaemia, should the risk of potential harm vs no potential benefit be taken into 
account?  
 
 What changed as a result of the paper? 
This piece had brought the subject of in-patient hyperglycaemia to greater prominence 
than it had previously. In particular it has highlighted the importance of looking for diabetes 
or hyperglycaemia in the hospitalised population. 
 
A national survey was undertaken in 2012 by my colleague Professor Mike Sampson, 
chair of the Joint British Diabetes Societies for In-patient Care Group. In that he asked 
every specialist diabetes team in the UK a number of questions on what they thought 
about the guidelines that the group had produced up to that time [123]. That showed that 
the vast majority of specialist diabetes teams found the JBDS guidelines useful and rated 
then as ‘very good’ or ‘excellent’. The data also found that, other than the peri-operative 
guideline, most acute Trusts had either adopted or adapted the JBDS guidelines, 
suggesting that despite the lack of hard evidence that glucose lowering made a difference 
to outcomes, that teams felt (‘intuitively’?) that normalising glucose concentrations was the 
correct course of action. The JBDS suite of guidelines ‘allowed’ them to do this (or rather 
almost gave them a license to do so), but also to do it across the UK in a consistent 
manner. Thus whilst the ‘Uncertainties’ piece was deliberately meant to be provocative, 
the overwhelming answer from practicing clinical teams to the question “Should in-patient 
hyperglycaemia be treated?” was “Yes!” 
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In retrospect, what should have been done differently? 
The original version of the manuscript was almost three times longer than that which was 
eventually published. I regret not being able to have the whole version published because 
that made the arguments clearer with more examples. However, due to constraints placed 
on me by the journal, it was limited to the document eventually published. 
 
Future work as a result of this publication 
This is ongoing. The clear message that came across from this, and from other work done 
prior to the publication of this manuscript – and subsequently, is that more high quality 
work needs to be done to gather the evidence to show that treating high glucose 
concentrations in the in-patient population safely results in better outcomes for patients.  
 
Confirmation of authorship 
Not needed because I was the sole author. 
 
 
External link to the paper on the journal website 
 
http://www.bmj.com/content/346/bmj.f134   
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Title of paper: 
Sampson MJ, Dozio N, Ferguson B, Dhatariya K (2007); Total and excess bed 
occupancy by age, speciality and insulin use for nearly one million diabetes patients 
discharged from all English Acute Hospitals. Diabetes Res Clin Pract 77: 92-98 
 
Impact factor of the journal 
2.54 
 
My contribution to this peer reviewed publication 
I was involved in the discussions about what outcomes should be measured and what 
analysis should be undertaken. I was also involved in the discussions about the 
manuscript preparation and revisions undertaken.  
 
Background to the paper 
Data from surveys undertaken in individual hospitals had shown that patients with 
diabetes spent longer in hospital that those without diabetes with the same condition or 
under the same admitting team. It had also been shown in data from the US that patients 
with diabetes had a longer length of hospital stay than those without diabetes admitted for 
the same condition and that this had significant economic consequences [124]. However, 
similar data was not available on a national basis in the UK.  
 
Objectives of the study 
This study was an ambitious attempt to collect data based on discharge summaries that 
make up the Hospital Episode Statistics (HES) data to look at length of hospital stay 
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depending on the speciality of the admitting consultant, broken down by medical and 
acute surgical sub-specialities.  
 
What this study added to the literature 
These data showed that, in agreement with the US data, patients with diabetes had longer 
lengths of hospital stay regardless of their admission speciality, accounting for up to 24% 
excess bed days. Whilst the increase length of stay was modest – rarely greater than 1 
day – in total, because people with diabetes accounted (at that time) approximately 10% 
of all in-patients, this still equated to a very large number of excess bed days. The data 
looked at the spread of these excess bed days across age and speciality and showed that 
excess length of stay decreased with age, with those with diabetes over the age of 75 
years having much the same length of stay as those without diabetes of the same age. 
 
What changed as a result of the paper? 
These data provided diabetes teams across the UK, and further afield, with sufficient 
information to convince hospital management that investing in in-patient diabetes services 
should be a priority. Furthermore, to show that fairly simple service redesigns could help to 
reduce in-patient bed usage, reduce length of stay, reduce medication use, mealtime and 
insulin errors, improve day case listing rates, reduce admissions, and be associated with 
higher satisfaction scores.  
 
In retrospect, what should have been done differently in this study? 
These data compared the discharge data for 943,613 people recorded as having diabetes 
compared to 10,724,414 people without diabetes over the four years that the study 
analysed. Other work presented earlier in this thesis has shown that coding data is 
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relatively poor, and thus in an ideal world, better quality data would have been used – i.e. 
individual patient data. However, discharge codes (and subsequent costs charged by 
hospitals to funders) are highly reliant on these documents. They are often lacking in 
sufficient detail. Individual patient notes could be looked at to ensure that the coding was 
correct – or at least ask individual hospitals to do an audit of the coding inaccuracies with 
their own institutions and then make the adjustments on the data based on their findings. 
Diabetes is often not reported in discharge summaries, and thus its impact is likely to be 
underestimated. 
 
Future work as a result of this publication 
These data have provided the foundation for further work on all aspects of in-patient 
diabetes – in terms of admissions avoidance and many other strategies to help reduce the 
length of stay. There have been attempts made to try and analyse where the delays occur 
in discharging patients and to quantify the economic impact of this excess length of stay. 
[8] 
 
Confirmation of authorship 
This is shown. 
 
 
External link to the paper on the journal website 
http://www.diabetesresearchclinicalpractice.com/article/S0168-8227(06)00455-4/pdf   
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Title of paper: 
Sampson MJ, Brennan C, Dhatariya K, Jones C, Walden E (2007); A national survey of 
in-patient diabetes services in the United Kingdom. Diabetic Med 24: 643-649 
 
Impact factor of the journal 
3.12 
 
My contribution to this peer reviewed publication 
I was involved in the initial discussions on the questionnaire development. I was also 
involved in the discussions about what outcomes should be measured and what analysis 
should be undertaken. I was also involved in the discussions about the manuscript 
preparation and revisions undertaken.  
 
Background to the paper 
As the prevalence of diabetes in the general population was rising, it was becoming more 
apparent that the numbers of hospital in-patients with diabetes was also increasing. 
However, it was also clear that the vast majority of patients with diabetes were not 
admitted because of a diabetes specific problem; rather they were admitted with diabetes 
being an additional diagnosis. This meant that these patients’ diabetes was being looked 
after by non-specialists. With the advent of new drug classes, new data on glycaemic 
targets, and new standards of care, it was becoming clearer that there was an increasing 
risk of harm – or rather, inappropriate management for patients in hospital.  
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Objectives of the study 
This study was a survey of all diabetes teams across the UK to assess what provisions for 
in-patients with diabetes were available. 
 
What this study added to the literature 
This was the first national survey of national in-patient diabetes services available in the 
UK. It was very representative, because 91.2% of all UK specialist diabetes teams 
responded. It showed that whilst most hospitals had a guideline for diabetic ketoacidosis, 
one third of all UK hospitals did not have a co-ordinated guideline for the management of 
the most common cause for an acute diabetes related hospital admission – the diabetic 
foot. Similarly, only a minority of hospitals had guidelines in place for managing 
hypoglycaemia or peri-operative diabetes care. Only 20.4% of responding hospitals had 
guidelines for all 10 conditions asked about. Furthermore, only 42.2% of hospitals had an 
in-patient podiatry service, and 58.3% of respondents said they had access to a dietitian 
able to see in-patients. Of more concern, however, was that despite the evidence for the 
benefits of an in-patient diabetes nurse service, only 51.4% of hospitals had one. Their 
workload and case mix was described. This was the first time that such an in-depth study 
of in-patient services had been carried out. 
 
 What changed as a result of the paper? 
These data have set much of the ground work for part of the National Diabetes In-patient 
Audit (NaDIA). This national audit has been carried out annually since 2011 (except for 
2014). This audit expanded the data collected to include more data on individual patient 
harms as well as staffing levels. The NaDIA data now forms a central part of the Care 
Quality Commission (CQC) pre-inspection packs. As a result of discussions between the 
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Joint British Diabetes Societies for In-patient Care Group and the CQC – I am one of 
those involved in these discussions – in-patient diabetes is one of the very few ‘condition 
specific’ quality indicators that the CQC ask about – the others being standards of care for 
people with dementia and for those with learning difficulties. The CQC now has a number 
of ‘key lines of enquiry’ around the care of people in hospital with diabetes. As of April 
2017, these are as follows: 
 
Evidence required: Prior to the inspection, and in discussion with Trust senior 
management, does the provider: 
 Participate in the annual NaDIA programme.  
 Have a credible and overarching written strategy for in-patient diabetes care across 
the entire Trust as part of an approved Trust governance framework.  
 Have a written policy for the safe prescribing and administration of insulin, linked to 
direct or online mandatory training of all staff, with evidence of adoption of national 
guidance on in-patient diabetes care and insulin use [101,125,126], and programmes 
to review improvement in outcomes.  
 Have a dedicated in-patient diabetes specialist service as one of their core services, 
with routine and planned access to this service for all in-patients with diabetes, not just 
emergency admissions [127].  
 Have a foot multidisciplinary team (MDT) for in patients with acute diabetic foot 
problems and /or high risk feet while in-patients. 
 Have a robust system in place to identify all current in-patients with a known diabetes 
diagnosis, with evidence of a rapid referral system to the specialist in-patient diabetes 
team for those experiencing diabetes management problems.  
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 Collect annually, and review, the in-patient experience of diabetes care, and the key 
issues raised, positive and negative. 
 
Intelligence: If the inspection team feels there is little evidence of the above elements of a 
good in-patient diabetes service in place, then review: 
 Severe in-patient hypoglycaemia rate by quartile against comparator Trusts (NaDIA 
data) 
 Insulin prescription error and management errors per year by quartile against 
comparator Trusts (NaDIA data) 
 Hospital acquired foot lesions against comparator Trusts (NaDIA data) 
 Access to the in-patient diabetes specialist team  
 Evidence of adoption, or adaption, of national insulin and in-patient diabetes 
management guidelines, and uptake of mandatory training in insulin management 
among all relevant staff. 
 Sample insulin prescription chart(s): Is the insulin correctly prescribed  
 Action taken at Trust and ward level for patients when glucose readings are at the 
extremes (very high or very low) – what action is taken, and by whom? 
 
During the inspection 
 The inspection team should ask ward managers and patients with diabetes about the 
specific issue of timing of insulin in relation to meals, and quality of meals and snacks  
 The inspection team should check that a foot assessment has been documented for 
all patients with diabetes during the current in-patient episode 
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 The inspection team should examine the insulin prescription chart. Is the name and 
dose of insulin correct? Is the timing of insulin correct? Is ‘unit’ written in full on the 
prescription? Is correct insulin administration equipment used.  
 The inspection team should ask junior doctors and nurses whether they have had 
training in insulin prescription and management at this Trust? Are they confident in 
insulin prescription and management?  
 
The start of the process – i.e. the publication of the initial paper – has led directly to the 
inclusion of diabetes as part of the CQC inspections for all Acute Hospitals 
 
In retrospect, what should have been done differently in this study? 
The very large changes that these data have resulted in over the years suggest that they 
are very robust. Thus, in retrospect, I do not feel that anything could have or should have 
been done differently at the time.  
 
Future work as a result of this publication 
NaDIA started in 2011 and has continued to be carried out annually since then, under the 
leadership and stewardship of Professor Gerry Rayman in Ipswich. In 2014 there was 
insufficient funding to enable NaDIA to be carried out nationally, but as a result of the data 
being part of the CQC inspection, it is now almost guaranteed to be funded from now on. 
The data generated form NaDIA continues to form the basis of much ongoing service 
improvement work in individual hospitals.  
  
Confirmation of authorship 
This is shown. 
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External link to the paper on the journal website 
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Title of paper: 
Sampson MJ, Crowle T, Dhatariya K, Dozio N, Greenwood, R, Heyburn PJ, Jones C, 
Temple RC, Walden E (2006); Trends in bed occupancy for in-patients with diabetes 
before and after the introduction of a diabetes in-patient specialist nurse service. Diabetic 
Med 23: 1008-1015 
 
Impact factor of the journal 
3.12 
 
My contribution to this peer reviewed publication 
I was involved in the discussions about what outcomes should be measured and what 
analysis should be undertaken. I was also involved in the discussions about the 
manuscript preparation and revisions undertaken.  
 
Background to the paper 
It had been recognised for many years that people with diabetes in hospital experienced 
problems with excess morbidity, prolonged length of stay and extreme dissatisfaction. 
These issues were long standing, systemic, and well described. However, there were few 
data available on what interventions made a difference to these findings. The background 
to this was the appointment to our hospital of one of the country’s first diabetes in-patient 
specialist nurse (DISN). At the time of her appointment in 2003/2004, the prevalence of in-
patient diabetes was much less than it currently is at 9.7%, compared to 17% in 2016 [2]. 
These data showed that a simple service redesign based around a dedicated in-patient 
diabetes specialist nurse team had been shown to reduce length of stay, reduce 
medication use, mealtime and insulin errors, improve day case listing rates, reduce 
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admissions, and be associated with higher satisfaction scores. However, it has been 
shown from the NaDIA data and older national surveys commissioned by the Association 
of British Clinical Diabetologists presented earlier in this thesis, that about one third of UK 
Trusts (particularly smaller Trusts) lacked this very simplest of service models. There was 
little incentive for Acute Trusts to improve or change, and it was felt that much of this poor 
quality practice (and acceptance of poor outcomes) had become embedded as part of 
‘normal’ Trust care.  
 
Objectives of the study 
The objective of the study was to provide accurate data for excess diabetes bed 
occupancy, and examine evidence of benefit for a diabetes in-patient specialist nurse 
(DISN) service model locally and nationally. 
 
What this study added to the literature 
The data presented in this paper helped to provide individual Trusts with the information to 
show that a small amount of investment could lead to substantial improvements in care, as 
well as significant cost savings. It was the first time that an accurate analysis of bed usage 
had been carried out showing the benefits of a diabetes in-patient specialist nurse. 
 
 What changed as a result of the paper? 
Other authors have also shown the benefits of an in-patient service [128]. These data, and 
those from NaDIA, show that the numbers of referrals to the DISN teams have been 
increasing year on year. However, despite the very strong evidence base supporting their 
use only two thirds of all acute hospitals now have a DISN available [101]. In addition, 
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there are not enough of them to see everyone, with the DISN’s themselves reporting that 
they are only being able to see two thirds of those they feel they ought to be seeing [101].  
 
As mentioned, many other teams across the UK and other parts of the world have seen 
the value of appointing in-patient nurses. The appointment of the DISN’s led to the 
formation of the UK DISN group, a founding partner in the JBDS Group. The original DISN 
appointed who was the centre of the paper, Esther Walden, has been the chair of the UK 
group since its inception. The JBDS group has published a large number of national 
guidelines for the management of in-patients with diabetes, with all of these having 
substantial input from the DISN’s. Thus this study had had direct impact on millions of in-
patients across the UK and the world.  
 
 
In retrospect, what should have been done differently in this study? 
This paper was amongst the first ever published to show the benefits of a dedicated in-
patient diabetes specialist nurse. The only thing that could have been done differently is 
perhaps doing it earlier. The reason it was not, is that it took a great deal of persuasion to 
convince our hospital of the potential value of such a nurse. That there was no data to 
support their appointment proved to delay them being put into place.  
 
Future work as a result of this publication 
The DISN group continue to play an integral role in the development and writing of all 
JBDS in-patient guidelines.  
 
Confirmation of authorship 
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External link to the paper on the journal website 
 
http://onlinelibrary.wiley.com/doi/10.1111/j.1464-5491.2006.01928.x/abstract   
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The Diabetes In-patient Treatment Satisfaction Study (DIPSat)   
119 | P a g e  
 
Title of paper: 
Sampson MJ, Singh H, Dhatariya KK, Jones C, Walden E, Bradley C (2009); 
Psychometric validation and use of a novel diabetes in-patient treatment satisfaction 
questionnaire. Diabetic Med 26: 729-735 
 
Impact factor of the journal 
3.12 
 
My contribution to this peer reviewed publication 
I was a co-applicant on this Diabetes UK funded research project. I was involved in the 
discussions when submitting the grant application. I attended most of the steering group 
meetings and actively participated in the discussions about what outcomes should be 
measured and what analysis should be undertaken. I was also involved in the discussions 
about the manuscript preparation and revisions undertaken.  
 
Background to the paper 
Having diabetes is associated with an almost doubling of risk for hospital admission for 
people with the condition, compared to those without diabetes who have the same 
condition [9]. The management of diabetes is often complex and the underlying medical 
condition that has necessitated hospital admission can change the day-to-day needs of 
the person with diabetes. This poses challenges for patients and their caregivers, because 
even in people who correctly self-manage their own diabetes, several things can change 
during the time of an acute illness that may influence glycaemic control. These include 
(but are not limited to), change of environment, change of diet and altered levels of intake, 
differing levels of physical activity, and the direct effects of the physical illness (e.g. being 
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nil by mouth before or after an operation, or post-operative nausea and vomiting). Added 
to this, it is well recognised that the doctors most frequently in contact with the patients – 
junior medical staff – have low levels of confidence and competence when dealing with 
diabetes [83]. Taken together, in the unfamiliar and often frightening atmosphere of an 
acute hospital admission, it was unknown how patients with diabetes felt about their care, 
and importantly what aspects of their care were most important in determining their levels 
of treatment satisfaction as an in-patient.  
 
On this background, funding was sought and awarded from Diabetes UK, to develop and 
validate a self-completed questionnaire that would appropriately assess the satisfaction of 
care provided to hospital in-patients with diabetes. 
 
Objectives of the study 
To develop the first psychometrically validated diabetes treatment satisfaction 
questionnaire for hospital in-patients. 
 
What this study added to the literature 
Prior to the publication of this paper there has been a lot of work done to assess patient 
satisfaction in people with diabetes with the treatment they had received as outpatients, or 
with other diabetes related complications [129-132]. However, nothing had been done to 
look at hospital in-patients with diabetes. This paper looked at the modification of existing 
outpatient questionnaires and added some questions to make them suitable for in-patient 
use. At the time of publication, it was a novel approach to an understudied subject in an 
increasing large proportion of hospital in-patients.  
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 What changed as a result of the paper? 
The number of hospital in-patients with diabetes is rising – the 2016 data from the National 
Diabetes In-patient Audit (NaDIA) showed that the range prevalence of diabetes across 
UK hospitals was a mean of 17%, and a range of 4% to over 35% [2]. The publication of 
this paper has led to an increased awareness of the importance of treating people with 
diabetes who are in hospital correctly. In particular the major issues surrounding the 
availability – in terms of timing and choice – of hospital food, as a source of major 
dissatisfaction in this population.  
 
In retrospect, what should have been done differently in this study? 
At the time that this study was first thought of and conducted, this was a novel idea. The 
use of other validated diabetes treatment satisfaction questionnaires was already 
established, and the validation of this tool for in-patients was the next obvious step. It was 
planned as a series of work that were all carried out. Thus, in retrospect, I do not believe 
that anything different should have been done.  
 
Future work as a result of this publication 
The next step was the production of a validated diabetes treatment satisfaction 
questionnaire in 5 South Asian languages. This work was done, and completed, and has 
been submitted for publication.  
 
Confirmation of authorship 
This is shown. 
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External link to the paper on the journal website 
http://onlinelibrary.wiley.com/doi/10.1111/j.1464-5491.2009.02754.x/abstract  
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Title of paper: 
Rutter CL, Jones C, Dhatariya KK, James J, Irvine L, Wilson EC, Singh H, Walden E, 
Holland R, Harvey I, Bradley C, Sampson MJ (2013); Determining in-patient diabetes 
treatment satisfaction in the UK—the DIPSat study. Diabetic Med 30: 731-738 
 
Impact factor of the journal 
3.12 
 
My contribution to this peer reviewed publication 
I was a co-applicant on this Diabetes UK funded research project. I was involved in the 
discussions when submitting the grant application. I attended most of the steering group 
meetings and actively participated in the discussions about what outcomes should be 
measured and what analysis should be undertaken. I was also involved in the discussions 
about the manuscript preparation and revisions undertaken.  
 
Background to the paper 
Having diabetes is associated with an almost doubling of risk for hospital admission for 
people with the condition, compared to those without diabetes who have the same 
condition [9]. The management of diabetes is often complex and the underlying medical 
condition that has necessitated hospital admission can change the day-to-day needs of 
the person with diabetes. This poses challenges for patients and their caregivers, because 
even in people who correctly self-manage their own diabetes, several things can change 
during the time of an acute illness that may influence glycaemic control. These include 
(but are not limited to), change of environment, change of diet and altered levels of intake, 
differing levels of physical activity, and the direct effects of the physical illness (e.g. being 
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nil by mouth before or after an operation, or post-operative nausea and vomiting). Added 
to this, it is well recognised that the doctors most frequently in contact with the patients – 
junior medical staff – have low levels of confidence and competence when dealing with 
diabetes [83]. Taken together, in the unfamiliar and often frightening atmosphere of an 
acute hospital admission, it was unknown how patients with diabetes felt about their care, 
and importantly what aspects of their care were most important in determining their levels 
of treatment satisfaction as an in-patient. This has always been a strong theme in patient 
comments and complaints, raised repeatedly by Diabetes UK over the last decade. In-
patients with diabetes are very vulnerable (particularly those on insulin) to variable meal 
times and meal quality, to nil by mouth policies and insulin management, and to the 
tendency of inexperienced clinical staff to take over insulin management and blood 
glucose monitoring, from often very experienced patients.  
 
This study was a follow on, a natural progression, from the development of the validated 
questionnaire described previously. This used the Diabetes In-patient Treatment 
Satisfaction Questionnaire to assess what insulin treated patients with diabetes felt about 
the care they received in hospital.  
 
Objectives of the study 
To use the first psychometrically validated diabetes treatment satisfaction questionnaire 
for hospital in-patients to examine what determinants of in-patient diabetes care were 
associated with treatment satisfaction or dissatisfaction.  
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What this study added to the literature 
This was the first time that patients has been surveyed to assess their perceptions of the 
quality of diabetes care, using a validated instrument, in such large numbers (n=1,319). 
The findings were novel, if not unsurprising, that in-patients with diabetes in hospital in the 
UK have high levels of dissatisfaction with their diabetes care. Many people were satisfied 
with their diabetes care in hospital, but there were very high levels of dissatisfaction with 
the timings and choice of available meals, with 23% saying they would rarely or never 
chose to eat the food they were offered in hospital, and that 20% of people reported 
having high glucose concentrations during their in-patient stay, and 7% has episodes of 
hypoglycaemia. 26% of respondents reported at least one episode of a glucose that was 
so low they required rescue treatment from a third party. All of these factors were 
associated with lower satisfaction scores.  
 
 What changed as a result of the paper? 
Prior to the publication of this paper, what patients with diabetes thought about their care 
whilst in hospital has not been deemed to be particularly important. Subsequently, other 
authors have cited this work in an attempt to raise this issue – and how it impacts on the 
overall patient experience and thus outcomes [133,134]. In addition, in-patient treatment 
satisfaction is now a prominent feature in the National Diabetes In-patient Audit (NaDIA) 
with the 2015 data showing that 34% of patients reported that their hospital sometimes, 
rarely or never provided the right choice of food to manage their diabetes [101]. 
 
In retrospect, what should have been done differently in this study? 
Due to logistical difficulties of using the questionnaires, and to try and keep the patient 
population sampled as ‘homogenous’ as possible, only those patients on insulin who were 
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seen by a Diabetes In-patient Specialist Nurse were approached to take part in the study. 
These represent a minority of diabetes patients – 35.6% of all patients with diabetes in the 
2015 NaDIA dataset [101], with the vast majority being on diet or oral hypoglycaemic 
agents only. These latter patients may have different experiences, but given the 
complexity of the study and the cost restraints, it was deemed not possible to be able to 
survey them.  
 
Future work as a result of this publication 
The next step was to develop a version of the Diabetes In-patient Treatment Satisfaction 
Questionnaire for five South Asian Languages, Hindi, Urdu, Bengali, Punjabi and Gujarati. 
Then to administer the questionnaire and compare the outcomes of in-patient diabetes 
treatment between people who described themselves at ‘White British’, those people who 
were of South Asian origin but said that English was their first language and those who 
used one of the 5 South Asian languages as their first language. This was done and the 
study completed. It has been submitted for publication. 
 
Confirmation of authorship 
This is shown. 
 
 
External link to the paper on the journal website 
 
http://onlinelibrary.wiley.com/doi/10.1111/dme.12095/abstract   
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The Management of Diabetic Ketoacidosis  
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Title of paper: 
Dhatariya KK (2007); Diabetic ketoacidosis. Br Med J 334: 1284-1285 
 
Impact factor of the journal 
17.4 
 
Background to the paper 
Prior the publication of the Diabetes Control and Complications Trial (DCCT) [4] and the 
United Kingdom Prospective Diabetes Study (UKPDS) [5] it had been recognised that long 
terms poorly controlled diabetes was associated with an increased risk of developing the 
microvascular and macrovascular complications of diabetes. What had not been 
demonstrated until those studies were published, was that if glycaemic control was 
improved, would it make a difference to the risk of developing complications. Both of these 
studies showed that good glycaemic control achieved early after the diagnosis of diabetes 
and then maintained for 6-7 years led to significant reductions in the risk of developing 
complications. These benefits were maintained many years later, even when the trials had 
stopped, and the glycaemic control in the intensive treatment arm had deteriorated once 
the trials had stopped – so called ‘metabolic memory’ [135,136].  
 
The management of hyperglycaemia in hospital in-patients reflects this history for 
outpatients with diabetes – there are currently plenty of data to suggest that in-patients 
with high glucose concentrations experience a variety of harms, but there are currently 
very few data to show that intervening makes a difference to outcomes.  
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In 2006 I was at event where one of the other guests was a local intensivist. Over the 
following hours we had a robust discussion. The main tenant of their argument was ‘why 
do physicians insist on using 0.9% sodium chloride solution (“normal saline”) as the fluid 
resuscitation of choice when treating DKA?’ Their vociferous argument went on for quite 
some time, and I was unable to counter the argument at that time, other than by saying 
‘this is how it has always been done, and there seems to be little evidence of harm’. As a 
result of this encounter I undertook a literature review of the arguments and was able to 
formulate this paper, which was eventually published in the BMJ.  
 
Objectives of the paper 
To argue the case (by providing evidence) for continued use of 0.9% sodium chloride 
solution as the fluid replacement of choice for people presenting with DKA. In addition, to 
argue against the use of alternative fluids, such as Hartmann’s solution. 
 
What this study added to the literature 
For many years there had been a debate about what was the best fluid to use in replacing 
the losses seen in patients presenting with DKA. There had been very few randomised 
controlled trials comparing the use of 0.9% sodium chloride solution with other crystalloids, 
e.g. Hartmann’s solution or Ringer’s lactate solution. This editorial explained the 
arguments for why most diabetologists have safely used 0.9% sodium chloride solution for 
many decades. It also argued why other solutions were not suitable because of the 
potential risks. This debate had not occurred in print for many years prior to this editorial 
being published.  
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What changed as a result of the paper? 
Within a few days of the editorial being published I began to get a lot of correspondence – 
predominantly from anaesthetists – personally and as ‘rapid reviews’ telling me (in no 
uncertain terms) that “I didn’t know what I was talking about”. The editorial has been cited 
23 times (accessed 1st October 2017), and has been cited in at least one subsequent 
randomised controlled trial comparing the use of different crystalloid solutions in this 
situation [137]. On a broader level, this paper opened up the discussion again about what 
is the best way of replacing fluids in this group of sick individuals. On reflection, it is now 
widely acknowledged, that there is no single ‘physiologically correct’ solution that currently 
exists that adequately replaces the fluid and electrolytes lost during an episode of acute 
DKA. 
 
On a personal level what changed for me is that this manuscript was read by the members 
of the JBDS DKA guideline writing group who at the time were in the earliest stages of 
formulating the guidance. They invited me to join the group and I have been a senior 
member of the JBDS steering group since then, where I have either been the lead co-
author, or a co-author on most of the guidelines written by the group. 
 
In retrospect, what should have been done differently? 
On reflection, I feel that I would have done nothing differently at that time. Diabetologists 
had used 0.9% sodium chloride solution safely for decades with no apparent evidence of 
harm, yet its use was consistently challenged by intensivists and anaesthetists, again, with 
no evidence of benefit for the alternatives they put forward. That the argument was 
opened up, that more work has been done subsequently, that the majority of specialist 
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diabetes teams across the UK continue to use 0.9% sodium chloride solution as first line 
fluid replacement of choice suggests that my argument has been supported. 
 
Future work as a result of this publication 
For me, this editorial was the start of the process that has got me deeply involved in a) 
collecting the data to show the harms associated with in-patient hyperglycaemia, and b) to 
allow me to work on projects to show that intervening will make a difference to outcomes. 
 
Confirmation of authorship 
Not needed because I was the sole author. 
 
 
External link to the paper on the journal website 
http://www.bmj.com/content/334/7607/1284   
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Title of paper: 
Savage MW, Dhatariya KK, Kilvert A, Rayman G, Rees JA, Courtney CH, Hilton L, Dyer 
PH, Hammersley MS (2011); Joint British Diabetes Societies guideline for the 
management of diabetic ketoacidosis. Diabetic Med 28: 508-515 
 
And the main document from which this paper was derived:  
 
Dhatariya K, Savage M, Kelly T, Sampson M, Walton C, Claydon A, Dyer P, Evans P, 
Khan A, Kilvert A, Leech N, Levy N, Rayman G, Rees A, Sinclair-Hammersley M (2013) 
Joint British Diabetes Societies In-patient Care Group. The management of diabetic 
ketoacidosis in adults. Second edition. Update: September 2013  
 
Impact factor of the journal 
3.12. Furthermore, in 2014, this paper was the 4th most downloaded manuscript from the 
Wiley online website (http://onlinelibrary.wiley.com) globally, and in 2015, it was the 3rd 
most downloaded manuscript from the website [data given to me verbally from 2 Associate 
Editors of the journal]. 
 
My contribution to this non-peer reviewed publication 
I was a senior member of the writing group. I attended all of the meetings and the 
teleconferences. I was actively corresponding by email to all of the other co-authors. I was 
involved in writing the first edition of the guideline. For the second edition, I was the 
person who co-ordinated the updates, and wrote the final draft of the guideline. It was not 
peer reviewed, because as the editor of the journal said to me when he received it ‘the 
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writing group is made up of enough experts in the field in the UK that it has already been 
peer reviewed in the writing process’. 
 
Background to the paper 
Despite their having been a progression of publications on the way DKA should be 
treated, in the early 1980’s there remained an appreciable mortality and morbidity [33]. 
This was despite using a regimen similar to the one used by many diabetes teams – low 
dose intravenous insulin infusion, aggressive fluid replacement and correction of 
electrolyte disturbances. However, what there seemed to be lacking was a formal 
definition of DKA and a standardised approach to exactly how much insulin, what fluid 
replacement and at what rate, and what electrolytes should or should not be replaced, and 
if they were to be replaced, how fast.  
 
Because there were no data about many of these unanswered questions, the JBDS group 
asked for a copy of the DKA guidelines from hospitals across the UK. The received 
dozens of these and they were all carefully analysed by the writing group for areas of 
commonality highlighted but also, more importantly, areas of differences in practice. The 
writing group then had several face to face meetings, and emails to thrash out what should 
evolve from these many documents. Over this iterative process, the first edition of the 
national guideline was written. It was acknowledged that this was a consensus document, 
which cited the evidence where it existed, but used a pragmatic, consensus based 
approach for where areas of controversy were apparent.  
 
However, within a few weeks of the first version of this guideline being published newer 
data were emerging, on the use of the protocol in ‘real world’ clinical practice and other 
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data, e.g. the differences between outcomes using 0.9% sodium chloride solution and 
Hartmann’s solution [138]. Soon after the publication of the first edition of these national 
guidelines, several abstracts were presented in local, regional and national meetings with 
a variety of messages. It became apparent that there were changes that needed to be 
made and these were outlined in the updated document.  
 
Objectives of the guideline 
To harmonise the management of DKA in different hospitals across the UK.  
 
What this study added to the literature 
This paper was the first national guideline for the management of DKA. The writing group 
were not aware of any other country that had produced such a guideline. I am still 
unaware of any other country in the world that has what we have in the UK – a 
standardised approach to the management of DKA for non-specialists. The paper also 
included a 1 page, easy-to-read and easy-to-follow guide on how DKA should be 
managed.  
 
In addition, the updated version of the guideline allowed further advertising and 
dissemination of the guideline by the bodies who make up the Joint British Diabetes 
Societies – i.e. Diabetes UK, The Association of British Clinical Diabetologists and the 
Diabetes In-patient Nurse Group. The data included in this updated online version made 
no formal changes to the management of patients with DKA, but gave more references as 
to why things had changed from the way things ‘used to be done’.  
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 What changed as a result of the paper? 
New words and abbreviations were added to the diabetes vocabulary as a result of this 
paper. In particular ‘VRIII’ – variable rate intravenous insulin infusion, and ‘FRIII’ – fixed 
rate intravenous insulin infusion. The former National Clinical Director for Diabetes, Dr 
Rowan Hillson, should be credited with this change.  
 
Other things that changed quite substantially in the management of patients with DKA 
were the continuation of long acting subcutaneous insulin in those already on it as well as 
their FRIII / VRIII. In addition, the guideline advocates that arterial blood gas 
measurements are not necessary because the differences between arterial and venous 
blood are not sufficiently large enough to change management [39]. In addition, venous 
blood gas measurements are associated with less morbidity than arterial blood gas 
sampling. Finally, the writing group strongly advocated the use of 0.9% sodium chloride 
solution as the fluid replacement of choice in DKA. 
 
One of the major concerns that I had as a result of the first and subsequent versions of the 
guideline was whether it worked – were patients benefitting from its use? Previous work 
had shown that the first version of the guideline was being used and was well received. A 
survey was sent out by the chair of JBDS, Professor Mike Sampson in autumn 2012 to all 
secondary care diabetes teams. 105 replies were received, with over 90% of respondents 
rated the first version of the JBDS DKA guidelines as ‘Excellent’ or ‘Good’ (Figure 1).  
 
However, as a result of this difficulty of knowing whether the guideline worked I carried out 
a survey on the management of DKA across the UK. Those data are discussed later in 
this thesis. 
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This work and the work that has arisen from it was part of the reason that I was shortlisted 
for the 2017 Royal College of Physicians Excellence in Patient Care Awards.  
 
In retrospect, what should have been done differently in this study? 
On balance, at the time I think that the writing group made every effort to ensure that the 
final document was as comprehensive as possible, and as evidence based as it could be. 
However, more efforts could have been made to engage other groups of people who were 
involved in the care of these ill patients, in particular to have anaesthetic input from an 
intensive care perspective. This was done for the second edition. Also, greater input from 
acute medicine would have been appreciated; however, one of the authors (Dr PH Dyer) 
was predominantly an acute physician at the time and did have that perspective when the 
document was written. 
 
In retrospect, I believe that the second version of the guideline was timely and showed 
that the JBDS group were ‘dynamic’. That we understood that times changed, and the 
evidence base changed, and thus we needed to be seen to be ‘proactive’ in our approach. 
I believe that this has been one of the strengths of the JBDS Group. The peri-operative 
guideline that I led the writing group for (discussed elsewhere in this thesis) also went 
through this process. Further updates of the DKA guideline and the peri-operative 
guidelines are due in 2017/2018. 
 
Future work as a result of this publication 
The work discussed later in this thesis shows that the second edition of this guideline was 
written because more evidence came out on why we made the recommendations that we 
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did. It was clear that changes needed to be made quite quickly, not only because of 
feedback from specialist diabetes teams across the UK, who were very quick to adopt or 
locally adapt the guidelines, but also because of new data that had been published. 
 
In addition, as a result of this difficulty of knowing whether the guideline worked I carried 
out a survey on the management of DKA across the UK. That is data is discussed in a 
subsequent section. This is the largest national survey on the management of DKA ever 
carried out.  
 
Confirmation of authorship 
This is shown. 
 
External link to the paper on the journal website 
http://onlinelibrary.wiley.com/doi/10.1111/j.1464-5491.2011.03246.x/abstract  
 
External link to the guidelines on the website of the Association of British Clinical 
Diabetologists 
http://www.diabetologists-abcd.org.uk/JBDS/JBDS_IP_DKA_Adults.pdf  
http://www.diabetologists-abcd.org.uk/JBDS/JBDS_IP_DKA_Adults_Revised.pdf  
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Figure 1 – Data from Mike Sampson. Feedback from 104 hospitals – first shown at Diabetes UK March 2013 
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Title of paper: 
Rudd B, Patel K, Levy N, Dhatariya K (2013); A survey of the implementation of the NHS 
diabetes guidelines for management of diabetic ketoacidosis in the intensive care units of 
the East of England. Journal of the Intensive Care Society 14: 60-64 
 
Impact factor of the journal 
Unknown. This is currently not a ‘listed’ journal. Google Scholar reports that this paper has 
been citied six times [accessed 1st October 2017] 
 
My contribution to this peer reviewed publication 
I was involved with the initial discussions about what should be involved in the data 
collection and what analyses should be done. I also helped write the final version of the 
submitted manuscript. 
 
Background to the paper 
With the publication of the first edition of the JBDS guidelines on the management of DKA 
in 2011 local, regional and national data – usually published in abstract form from 
individual secondary care diabetes teams – suggested that they had a high level of 
acceptance, with the majority of teams either adopting them or adapting them for their own 
use. This was confirmed by a national survey carried out my Professor Mike Sampson, 
Chair of JBDS and presented at Diabetes UK Annual Professional Conference in 2013 
[123]. In the US and in the UK, it is strongly recommended that patients presenting with 
moderate or severe DKA be cared for in a high dependency unit (HDU) or intensive care 
unit (ITU) [20,42]. However, in the UK only a minority of patients presenting with DKA are 
looked after in these, level 2 (HDU), or level 3 (ITU) environments. Partly because of the 
144 | P a g e  
 
relative unavailability of HDU/ITU beds in the UK [139]. However, many intensive care 
units are ‘closed’ units. This means that they are run predominantly by teams who 
specialise in intensive care. This approach has been known to improve patient outcomes 
for over 20 years [140]. Thus, this approach does rely on the intensive care team to stay 
up to date with all aspects of critical illness. With the best will in the world, it is hard to 
keep up to date with the developments in all areas of ones’ speciality. This study aimed to 
look at the knowledge of, uptake and utilisation of the JBDS DKA guideline 18 months 
after the initial edition had been published, in 13 ITU’s across the East of England.  
 
Objectives of the study 
To audit critical care units within hospitals in the East of England and find out whether they 
had changed their DKA guidelines and adopted the ‘gold standard’ recommendations from 
the JBDS. In particular focussing on the introduction of weight based fixed rate 
intravenous insulin infusions, use of ketone meters, choice of resuscitation fluid, and 
continuation of basal long-acting insulin analogues. 
 
What this study added to the literature 
The data confirm that most units had their own DKA protocols but that most had not 
adopted or adapted the JBDS guidelines. Almost all of the units were run by anaesthetists 
and as such over half used Hartmann’s solution as their preferred resuscitation fluid; over 
half did not use the recommended fixed rate intravenous insulin infusion and 4 of the 13 
units had not updated their DKA guidelines since 2010 (with a further 2 not being sure or 
data unavailable). In addition, only 3 units had changed their practice to continue long 
acting subcutaneous insulin in addition the intravenous insulin infusions. The data also 
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suggested that there was either a lack of knowledge about the guideline or that there was 
resistance to its use.  
 
 What changed as a result of the paper? 
There was a concerted push to make more ITU teams know about the JBDS guideline 
after publication of this paper in the main UK ITU journal – published by the UK Intensive 
Care Society. In addition, my lead co-author, Dr Nicholas Levy has been instrumental in 
bringing the guidelines to ITU teams across the East of England and more widely by his 
frequently run anaesthetic conferences at the Association of Anaesthetists of Great Britain 
and Ireland (AAGBI).  
 
In retrospect, what should have been done differently in this study? 
It is clear that one of the reasons for the lack of uptake of the first edition of the guidelines 
is that no anaesthetists were involved in the writing group. There had been very little 
attempt to engage with other teams that were involved in the management of DKA, in 
particular the acute physicians. This changed with the second edition, where we had 
anaesthetic input at the very start as part of the writing group, and the document had 
endorsement from the Intensive Care Society 
 
Future work as a result of this publication 
It is hoped that this survey can be repeated to see if things have changed since the 
publication of the second edition.  
 
Confirmation of authorship 
This is shown. 
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External link to the paper on the journal website 
 
http://journals.sagepub.com/doi/pdf/10.1177/175114371301400112   
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Title of paper: 
Dhatariya KK, Nunney I, Higgins K, Sampson MJ, Iceton G (2016); A national survey of 
the management of diabetic ketoacidosis in the UK in 2014. Diabetic Med 33: 252-260 
 
Impact factor of the journal 
3.12 
 
My contribution to this peer reviewed publication 
I conceived the idea of the national survey. I wrote the data collection tool. I wrote to all 
diabetes teams in the UK and collected all the data. I helped analyse the data and came 
up with the interpretations. I wrote the initial and final drafts of the manuscript. 
 
Background to the paper 
It was a common anecdotal experience as a trainee that when one changed to a new 
hospital as a diabetes registrar to be asked to ‘re-write the DKA guideline’. There was 
often no justification to do so, other than to ensure that the most up-to-date literature was 
incorporated. However, there was little data to show that any particular version of a 
guideline actually worked. The history and evolution of the management of DKA is 
discussed at the start of this thesis, but in the 1980’s when a standardised regimen of low 
dose intravenous insulin infusion, aggressive fluid replacement and correction of 
electrolyte disturbances had been established, there was still a significant mortality [33]. 
There had been little data collected in the UK on outcomes of DKA, except for a notable 
paper in 1993 describing the persisting mortality associated with the condition [141]. It was 
against this background of small variations in care between hospitals, and no assessment 
of their outcomes that the first version of the national guideline was published. The second 
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edition incorporated new data and further justification for the suggested changes in 
‘accepted dogma’. However, what had not been done was an assessment of whether the 
guideline actually worked. Thus I created the 5 page questionnaire, and with the help of 
the mailing lists from JBDS, Diabetes UK, ABCD and the DISN group, I invited every 
secondary care diabetes team to submit data on the next 5 patients looked after in their 
Trust with a diagnosis of DKA. This questionnaire is listed as an appendix in the published 
paper. However, the questions asked are listed in Tables 1-5 in the paper. 
 
220 teams were invited to submit data, and 283 forms were received from 72 hospitals 
between May and November 2014 
 
Objectives of the study 
To examine outcomes of adult patients presenting with DKA in 2014, mapped against 
accepted the UK national guidance. 
 
What this study added to the literature 
Several new things were shown in the data.  
 The median time from admission to diagnosis was 35.5minutes  
 That the time to starting 0.9% sodium chloride solution was 6 minutes later and the time 
taken to start an intravenous insulin infusion was 60 minutes after admission 
 The data showed that more than 80% of UK hospitals were using the JBDS guideline.  
 Median time to biochemical resolution of DKA was 18.77 hours 
 8% of all cases of DKA were in existing hospital in-patients 
 Unlike previous data that suggested between 25-30% of all cases of DKA were newly 
presenting cases of type 1diabetes [142-147], our data showed that newly diagnosed 
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type 1 diabetes only accounted for 6.1% of cases, with infection and non-compliance 
accounting for most cases 
 Hypoglycaemia (glucose <4.0mmol/l) occurred in 27.6% and hypokalaemia 
(<4.0mmol/l) occurred in 67% of the patients. These data are similar to the rates seen 
in single centre studies recently reported [148,149]  
 The guidelines were often not followed with respect to the use of a VRIII, potassium 
replacement and the introduction of 10% glucose at the appropriate time  
 During the study, only 1 person died, but that was several months after the initial 
admission for DKA, and the cause of death was listed as osteomyelitis  
 
What changed as a result of the paper? 
The data were only published in February 2016, but as of 1st October 2017 the paper had 
been citied 20 times. In addition, these data have been presented by me at several 
national and international meetings, in particular to discuss the significance of the 
hypoglycaemia and hypokalaemia. A possible reason for this could be the continuing fixed 
rate intravenous insulin infusion that continues even when glucose concentrations drop 
until ketone concentrations come down. This will continue to drive potassium 
concentrations down. The arguments are that either insulin infusion rates reduce when 
glucose concentrations drop, or the rate of potassium replacement should be increased. 
However both of these solutions have potential problems. 
 
If the insulin infusion rate were to decrease (e.g. from 0.1unit/Kg/hr to 0.05unit/Kg/hr), then 
there is a risk that the time taken for the DKA to resolve would lengthen and thus the 
patient would stay in hospital for longer. 
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If the potassium infusion rate were to be increased, this would necessitate a central 
venous catheter, and the patient would need to be in a monitored bed in a level 2 (HDU) 
or level 3 (ITU) environment. In the UK it has recently been reported that we have the 
lowest number of ITU beds in Europe [139]. 
 
When I have presented these data there has been discussion in open fora on whether 
these guideline should be changed. There has been overwhelming feeling that they should 
remain unchanged because many of these findings may represent the guidelines not 
being followed, rather than them being wrong. 
 
This work and the work that has arisen from it was part of the reason that I was a finalist 
for the 2017 Royal College of Physicians Excellence in Patient Care Awards.  
 
In retrospect, what should have been done differently in this study? 
The main piece of data that was not collected was the change in glucose over time. In 
addition, it was only after the data collect finished and the data published that I realised 
that it could be used to generate an analysis on how much it costs to treat an episode of 
DKA. This work has now been done, and has been accepted for publication. However, the 
major strengths of that paper are that it is a ‘bottom-up’ approach using individual patient 
care data, but despite this, several assumptions have had to be made.  
 
Future work as a result of this publication 
As the data were being collected, I was contacted by Dr Julie Edge, a consultant 
paediatrician from Oxford, who is a world expert on paediatric DKA. She wanted to 
conduct a very similar survey for adolescents presenting with DKA using the same 
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questionnaire, but adapted for an adolescent patient group. This data was collected in 
2014/2015 and is presented elsewhere in this thesis. 
 
Furthermore, as mentioned work has been done and submitted for publication on an 
economic analysis of DKA admissions. Now that this work has been completed for the 
adult population, it will be repeated for the adolescent dataset. 
 
One of the next pieces of work that has been done is to see if the results from a national 
survey are applicable to individual hospitals. Thus I have supervised 3 medical students 
who have collected data on 51 consecutive admissions with DKA to the Norfolk and 
Norwich University Hospitals NHS Foundation Trust using the same data collection form 
for the national dataset. These data have recently been published [150], and whilst they 
would fit well in this thesis, they are not included. They show very similar findings in most 
areas or care, suggesting that the national survey findings are indeed, applicable to 
individual hospitals.  
  
Confirmation of authorship 
This is shown. 
 
External link to the paper on the journal website 
http://onlinelibrary.wiley.com/doi/10.1111/dme.12875/abstract   
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Title of paper: 
Dhatariya K, Nunney I, Iceton G (2016); Institutional factors in the management of adults 
with diabetic ketoacidosis in the UK: results of a national survey. Diabetic Med 33: 269-
270 
 
Impact factor of the journal 
3.12 
 
My contribution to this peer reviewed publication 
I conceived the idea of the national survey. I wrote the data collection tool. I wrote to all 
diabetes teams in the UK and collected all the data. I helped analyse the data and came 
up with the interpretations. I wrote the initial and final drafts of the manuscript. 
 
Background to the paper 
I led the writing group for the second edition of the national DKA guideline. However, as 
part of this I wanted to know whether the guidelines actually worked. In addition, in my role 
as a senior member of the JBDS, and one of the few people who had been co-authors on 
all of the guidelines published to that point, I was often asked whether some form of work 
could be done to help teams assess how they were doing compared with others. Thus I 
carried out the world’s largest national survey on the management of DKA. This consisted 
of two parts, one part is presented earlier in this thesis, on individual patient management, 
but the other part, presented here, was a single page of questions assessing the factors 
that may have limited teams from delivering the care that they may have wished to when 
treating patients admitted with DKA. Whilst there are overarching data from the National 
Diabetes In-patient Audit (NaDIA) [101], there are very few individual institutional data 
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such as this available. Of the 220 UK diabetes secondary care teams invited to participate, 
67 hospitals returned the questionnaire. Data were collected on glucose meter availability, 
ketone meter availability and personnel availability. In addition, the questionnaire asked 
whether teams regularly reviewed their cases of DKA, and whether regular education was 
held for medical and nursing staff.  
 
Because JBDS had published guidance on diabetes self-management in hospitalised in-
patients [151], there were also questions asking whether this was possible in their Trust.  
 
Objectives of the study 
To examine the services provided by and facilities available to diabetes specialist teams 
and the institutional factors involved in the ability to provide comprehensive care for adult 
patients presenting with DKA in 2014. 
 
What this study added to the literature 
There were almost no data of a similar nature ever previously published, thus this is a way 
of documenting where secondary care diabetes teams in the UK are with respect to 
recommendations from national bodies. In addition, because the JBDS guidelines are in 
many ways ‘aspirational’, i.e. ‘This is what we believe a good diabetes service should 
have’, then more teams will hopefully be able to use these data to enable improvements in 
their own services.  
 
 What changed as a result of the paper? 
As of 1st October 2017, these data have been cited three times, but the data were only 
published in February 2016.  
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This work and the work that has arisen from it was part of the reason that I was a finalist in 
the 2017 Royal College of Physicians Excellence in Patient Care Awards.  
 
In retrospect, what should have been done differently in this study? 
That only 30% of all UK hospitals replied was a little disappointing. Thus, there was 
always the risk of reporting bias. I am aware, having filled out the forms myself that they 
were time consuming. There was no funding available to carry out this work, and thus 
teams did so out of good will. If future work were to be carried out, then I would have 
sought funds to allow teams to have been compensated for their time. This may have 
increased the return rate, thus increasing the generalisability of the work. 
 
Future work as a result of this publication 
This works needs to be repeated in the next 5 years or so. As the numbers of people with 
diabetes continue to rise, it is very likely that the numbers of people admitted with DKA will 
also continue to rise. The correct management of these individuals is of paramount 
importance, and the availability of appropriately educated staff and equipment is key. I 
would hope that the data presented in this paper serves as a start so that changes over 
time can be monitored. 
 
Confirmation of authorship 
This is shown. 
 
External link to the paper on the journal website 
http://onlinelibrary.wiley.com/doi/10.1111/dme.12877/full   
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Title of paper: 
Edge JA, Nunney I, Dhatariya KK (2016); Diabetic ketoacidosis in an adolescent and 
young adult population in the UK in 2014: a national survey comparison of management in 
paediatric and adult settings. Diabetic Med 33:1352-1359 
 
Impact factor of the journal 
3.12 
 
My contribution to this peer reviewed publication 
Dr Julie Edge conceived the idea of the national survey based on the work I had done in 
adults. I co-wrote the data collection tool. I collected all the data. I helped analyse the data 
and came up with the interpretations with Dr Edge. I helped write the initial and final drafts 
of the manuscript. 
 
Background to the paper 
I had led the writing group for the second edition of the national guideline on the 
management of adult patients with diabetic ketoacidosis (DKA) produced under the 
auspices of the Joint British Diabetes Societies for In-patient Care group. As mentioned 
elsewhere in this thesis, whilst I was aware that these guidelines had been well received 
and widely used [123], I had no idea whether they actually worked. This uncertainty is 
what led to me conduction the national survey that was discussed earlier in this thesis.  
 
The survey was initially designed to be carried out in the adult population, however, I was 
contacted by Dr Julie Edge, consultant paediatric endocrinologist in Oxford, and one of the 
worlds’ foremost authorities on paediatric DKA to ask if she could adapt and use the form 
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that I had created for the adult survey to conduct a similar one in the adolescent 
population. This led to the development of the questionnaire is given as an appendix in the 
published paper.  
 
Part of the reason for this, was to find out if there were differences in the way adolescents 
were treated compared to adults. Part of this lies in the reason why the JBDS adopted the 
weight based, fixed rate intravenous insulin infusion rate, something that was a change 
from what had previously been done in adults which was to use a fixed rate intravenous 
insulin infusion (FRIII) at ~6 unit per hour (or something similar) that varied depending on 
where you worked. The weight based regimen had been advocated for use in children for 
many years [152], based on work done in the 1970’s [153]. The question that the adult 
writing group had asked was ‘when does a child become an adult?’ Thus when should one 
move from the weight based FRIII to a non-weight based, empirical FRIII? The adult 
writing group could not decide, because we had all seen 14 year old children who were 
fully grown in adult stature, and also 18 year olds who were physically tiny. Thus, for the 
adult guideline one of the major shifts in the treatment paradigm had been the move to 
using the weight based, FRIII [42].  
 
Similar to the reason for why I conducted the adult survey, Dr Edge wanted to see if the 
guidelines used across the UK actually worked. The guidelines most commonly used were 
those from the International Society for Pediatric and Adolescent Diabetes and the British 
Society for Paediatric Endocrinology and Diabetes [154,155]. 
 
Objectives of the study 
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The aim of this joint survey was to examine the quality of management of young people 
(under the age of 22 years) against the JBDS guidelines in adult services [42], and the 
BSPED guidelines for paediatric services [155], and study the differences in management 
and outcomes. 
 
What this study added to the literature 
This study was the first of its kind – a nationwide survey of clinical practice in these 
patients. The data showed that most units used the BSPED guidelines, and that there 
were several similarities in the care received by the 14-22 year olds who presented with 
DKA, than those patients who were in the adult survey. These similarities included a 
significant proportion of patients treated using the guidelines developed either 
hypoglycaemia, or hypokalaemia. These would suggest that either the guidelines were not 
being followed, or the guidelines are wrong. Currently, when the data collected in the adult 
and adolescent surveys suggest that the guidelines are not being appropriately followed, 
then it is difficult to justify changing the guidelines 
 
 What changed as a result of the paper? 
Whilst the paper was accepted for publication in February 2016, it was only published in 
the paper edition of the journal in September 2016, thus it has not had enough time for 
any change to have been implemented since publication.  
 
In retrospect, what should have been done differently in this study? 
Currently it is too early to know if anything should have been done differently. It is the first 
national survey of its kind in the world, and thus sets the benchmark for other countries to 
so something similar.  
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Future work as a result of this publication 
I have been working with the paediatric department at the Norfolk and Norwich University 
Hospitals NHS Foundation Trust to look at the management of DKA in children – i.e. from 
1 to 17 years, admitted with the condition between 2012 and 1014 (n=99). These found 
that a significant proportion of those with suspected DKA did not fulfil the BSPED criteria. 
In addition – as with the adult and adolescent surveys – there were significant areas 
where guideline adherence and management was suboptimal. However, even when the 
guidelines were adhered to, there was still a high incidence of hypokalaemia and 
hypoglycaemia, suggesting that the 2009 guidelines were insufficient at preventing 
possible harm. As of October 2017 these data have been revised and re-submitted for 
publication. 
 
More work has also been done looking at the utility of ketone measurements in the 
diagnosis of DKA in children. This work has looked at all admissions with suspected DKA 
and plotted the pH with plasma ketone concentrations and glucose concentrations. This 
work has shown that the sensitivity and specificity to be able to diagnose DKA is greatest 
when the ketone concentrations are 4.4 mmol/l, not at the 3.0 mmol/l that the current 
ISPAD and BSPED guidelines recommend. As of October 2017 these data are being 
prepared for submission for publication.  
 
In addition, I am now part of the discussions taking place to look at the care of those aged 
between 16 and 18 years old. These adolescents will most often be under the outpatient 
care of the paediatricians / transition team, but if they are admitted to hospital then they 
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are most often under the care of the adult diabetes team. The JBDS guideline is for 18 
years old and above, yet if admitted, 16-18 year olds should be treated using the BSPED 
guideline which most adult teams do not use or know about. Thus there is a move to try 
and unify the guidelines for this age group. This is a work in progress. 
 
Confirmation of authorship 
This is shown. 
 
External link to the paper on the journal website 
http://onlinelibrary.wiley.com/doi/10.1111/dme.13065/full   
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Peri-operative Diabetes Care  
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Title of paper: 
Dhatariya K, Levy N, Kilvert A, Watson B, Cousins D, Flanagan D, Hilton L, Jairam C, 
Leyden K, Lipp A, Lobo D, Sinclair-Hammersley M, Rayman G (2012); NHS Diabetes 
guideline for the perioperative management of the adult patient with diabetes. Diabetic 
Med 29: 420-433 
 
And the main document from which this paper was derived:  
 
Dhatariya K, Flanagan D, Hilton L, Kilvert A, Levy N, Rayman G, Watson B, Cousins D, 
Jairam C, Leyden KM, Lobo DN, Sinclair-Hammersley M (2015) Management of adults 
with diabetes undergoing surgery and elective procedures: Improving standards. Revised 
September 2015  
 
Impact factor of the journal 
3.12. Furthermore, in 2014, this paper was the 5th most downloaded manuscript from the 
Wiley online website (for website see below) globally, and in 2015, it was the 4th most 
downloaded manuscript from the website [data given to me verbally from 2 Associate 
Editors of the journal]. 
 
My contribution to this non-peer reviewed publication 
I was a senior member of the writing group. I attended all of the meetings and the 
teleconferences. I was actively corresponding by email to all of the other co-authors. I was 
involved in writing the first edition of the guideline. For the second edition, I was the 
person who co-ordinated the updates, and wrote the final draft of the guideline. It was not 
peer reviewed, because as the editor of the journal said to me when he received it ‘the 
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writing group is made up of enough experts in the field in the UK that it has already been 
peer reviewed in the writing process’. 
 
Background to the paper 
There have been several studies showing that hyperglycaemia in the post-operative 
period is associated with harm. These include (but are not limited to) general surgery 
[11,71], cardiac surgery [156], vascular surgery [157,158], neurosurgery [159], orthopaedic 
surgery [160,161], colorectal surgery [162], trauma [163], breast surgery [164], liver 
transplantation [165], hepato-billiary and pancreatic surgery [166], cholecystectomy [167], 
and foot and ankle surgery [168]. These harms include wound infection, length of time in 
hospital, acute kidney injury, myocardial infarction, time spent on Intensive Care Unit or on 
a ventilator and death. The perioperative mortality rate is up to 50% higher than the non-
diabetes population [11]. Because of these factors, and the data to show that people with 
diabetes are less likely to be offered day case surgery and are more likely to have 
emergency surgery, have longer lengths of stay following admission and have a higher 
rate of 28 day readmissions following surgery [90], it would seem sensible to optimise 
glycaemic control prior to surgery and around the time of the operation. However, this 
optimisation would require a great deal of co-ordination between all the people involved in 
the care of the person with diabetes. In addition, as discussed elsewhere in this thesis, 
these data show that whilst there is evidence to show that high peri-operative glucose 
concentrations are associated with harm (using whatever measure of harm chosen), there 
are no data (other than in cardiac and liver transplant surgery) to show that correction of 
glucose concentrations is associated with improved outcomes. However, despite this lack 
of evidence it was felt that the approach that should be taken was that of ‘the absence of 
evidence does not mean the absence of effect’. Thus the Joint British Diabetes Societies 
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for In-patient Care Group formed a writing group to create these guidelines. I was the lead 
of this group, and the subsequent lead author on the guideline.  
 
Objectives of the study 
To harmonise the perioperative care of adult patients with diabetes undergoing surgery or 
procedures across the UK.  
 
What this study added to the literature 
For the first time, a document had appeared that ensured that glycaemic control was high 
on the agenda of surgeons and anaesthetists. Despite the huge amount of data to show 
that high glucose concentrations peri-operatively were associated with harm, it was a 
common finding for anaesthetists to allow ‘permissive hyperglycaemia’ to ensure that 
patients were not hypoglycaemic whilst under anaesthetic. In addition, it was clear that 
there was no accountability for the glucose amongst surgical or anaesthetic teams. In one 
of the documents published by the Royal College of Surgeons in 2011 entitled “The Higher 
Risk General Surgical Patient: towards improved care for a forgotten group”, the word 
‘diabetes’ appears only once, and the term ‘hyperglycaemia’ does not appear at all [169].  
 
This ground-breaking guideline covered the entire patient journey from the time of referral 
from primary care through to discharge home. Each section has the aims of needed to be 
achieved at each of the seven steps (referral from primary care, surgical outpatient, pre-
operative assessment clinic, hospital admission, theatres and recovery, post-operative 
care and discharge). In addition, each section has aims and recommendations. 
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The guideline also had sections covering the factors that lead to adverse outcomes, and 
also a section on standards of care (these came with defined audit standards). There was, 
as with many of the other JBDS guidelines, a section on controversial areas. This is 
because, for many of the recommendations there was no trial evidence and many of them 
were based on consensus. There were also several appendices that included how to 
manipulate oral and injectable glucose lowering agents on the day prior to surgery and on 
the day of surgery to ensure that patients with diabetes could be admitted on the day of 
surgery – something that had previously been shown to be lacking for patients with 
diabetes [8]. 
 
 What changed as a result of the paper? 
Several things have changed since this guideline was published. In 2013 my colleague 
Professor Mike Sampson, chair of the JBDS-IP Group presented data from a national 
survey of all diabetes teams across the UK to see what they felt about the JBDS 
guidelines [123]. That showed that the peri-operative guideline had been the one that had 
been the hardest to implement. This is because it involved many different specialities – 
primary care, surgeons, anaesthetists, pre-operative assessment clinic nurses and so on. 
People who do not usually have diabetes care in the forefront of their minds when looking 
after their patients. However, more recently, the Association of Anaesthetists of Great 
Britain and Ireland formed a working party on this subject, that I was a part of, and 
produced their own version of the guideline that was recently published in their main 
journal [170]. In addition, because of this, glycaemic control is to be included in the 2017 
edition of the Guidelines for the Provision of Anaesthetic Services (GPAS) produced by 
the Royal College of Anaesthetists. 
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Furthermore, the National Institute for Health and Care Excellence, have recently 
produced an updated a guideline for pre-operative tests [171]. This states that all patients 
known to have diabetes should have an HbA1c measured within 3 months of their 
procedure, although I have argued that NICE have missed out on an opportunity to do 
more good [172]. 
 
In retrospect, what should have been done differently in this study? 
I believe that this guideline has been revolutionary for the care of patients with diabetes 
undergoing surgery. It is an evolving document, and has taken into account the 
appearance of new drug classes since it was first published, as well as taking into 
consideration new safety data with some of these drugs. Given the slow pace of change in 
the UK National Health Service generally, I am aware that embedding glycaemic control 
into the culture of surgeons will take time, but this has been the start. Thus I do not feel I 
would have done anything differently. 
 
Future work as a result of this publication 
A lot of work has taken place and is planned as a result of this guideline. In 2016, the 
Health Technology Assessment Programme put out a call (HTA Number 16/25: Poorly 
Controlled Diabetes and Outcome in Elective Surgery). However, I wrote to them telling 
them, that on the basis of the most up-to-date evidence they were asking the wrong 
question. This was because most of the data now showed that those people who were 
known to have diabetes did relatively well compared to those who had previously 
undiagnosed diabetes / hyperglycaemia who did the worst. The plan should have been 
firstly to identify those who had previously undiagnosed diabetes / hyperglycaemia and 
see what their post-operative outcomes were compared to those who did not have 
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diabetes or were normoglycaemic. Secondly, if the first dataset showed a difference in 
outcomes, then to design an intervention to show an improvement. This work is currently 
in its early stages, and I am leading a group of interested individuals from across the UK to 
set up and run a multi-centre large trial with a sample size of 15,350. This sample size is 
based on several sources of evidence: 
a) The mean length of stay for all patients with diabetes admitted to the Norfolk and 
Norwich during 2015 was, on average 1.8 days longer than for those without diabetes. If 
‘zero length of stay’ patients were excluded (i.e. day cases) then the mean LOS was 2.7 
days longer than those without diabetes (SD~12 days).  
  
b) My colleague Professor Mike Sampson is running the worlds’ largest diabetes 
prevention study. He has now screened over 10,000 people who are at risk of getting 
diabetes – i.e. >40 years old, or BMI>30Kg/m2, or previous history of gestational diabetes 
or family history of diabetes. He has shared his (as yet unpublished) data with me, and he 
has found that the current prevalence of previously undiagnosed diabetes in this cohort is 
4.6%. There are some limitations with his data – i.e. this is a predominantly Caucasian 
population, and is selected to increase the chance of getting the population he needs for 
his study. Being white means that the prevalence is likely to be an underestimate 
compared to the UK average, but directing the recruitment to those at risk, will increase 
the prevalence. We have also looked at the Public Health England estimates, which 
suggest a prevalence of undiagnosed diabetes of 2.3% (95%CI 2.1, 2.6) and non-diabetic 
hyperglycaemia prevalence of 10.7% (95%CI 10.2, 11.1). 
  
If we use length of stay as our outcome, looking at these data he has calculated a sample 
size required would be 600 in each group. Thus if the prevalence is ~4.5% and this is 600, 
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then the target recruitment size will need to be 15,350 or so (allowing for a 15% drop out). 
That would give us sufficient number of people with diabetes, those with non-diabetic 
hyperglycaemia, and a large number of people without either with whom to compare.  
 
In addition, we have recently completed a study that looked at the quality of GP referral 
letters to all surgical specialities across 10 hospitals across the East of England and used 
the suggested referral form in the guideline as the template. These data were recently 
accepted for publication (Pournaras DJ, Photi ES, Barnett N, Challand CP, 
Chatzizacharias N, Dlamini N, Doulias T, Foley A, Hernan J, Kumar B, Martin J, Nunney I, 
Panagiotopoulou I, Shivakumar O, Sengupta N, Sinclair P, Stather P, Than MM, Wells AC, 
Xanthis A, Dhatariya K. Assessing the quality of primary care referrals to surgery of 
patients with diabetes in the East of England: A multi-centre cross-sectional cohort study. 
International Journal of Clinical Practice. DOI: 10.1111/ijcp.12971). 
 
Finally, the National Confidential Enquiry in Patient Outcomes and Death (NCEPOD) took 
up peri-operative care as one of their major themes during 2017 – 2019. I am part of the 
steering group for that work. It is due to look at a number of factors in the care of adult 
patients (over 16 years old) undergoing surgery – elective or emergency. This is still a 
work in progress.  
 
Confirmation of authorship 
This is shown. 
 
External link to the paper on the journal website 
http://onlinelibrary.wiley.com/doi/10.1111/j.1464-5491.2012.03582.x/full  
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External link to the guideline on the website of the Association of British Clinical 
Diabetologists 
http://www.diabetologists-abcd.org.uk/JBDS/JBDS_IP_Surgical_Guideline_2015_Full.pdf  
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Title of paper: 
Rollins KE, Varadhan KK, Dhatariya K, Lobo DN (2016); Systematic review of the impact 
of HbA1c on outcomes following surgery in patients with diabetes mellitus. Clin Nutr 35: 
308-316 
 
Impact factor of the journal 
4.49 
 
My contribution to this peer reviewed publication 
I was involved in the discussions about what questions should be asked by the systematic 
review prior to it starting. I was then involved in the discussions with the authors on each 
draft of the manuscript on how the data should be presented and what they meant. I 
helped to write the final version of the manuscript 
 
Background to the paper 
As I led the writing group for the national guideline written by the JBDS-IP group on the 
peri-operative management of patients with diabetes undergoing surgery or procedures it 
became clear as the various papers were being reviewed that there were differences in 
what different authors thought of as ‘glycaemic control’. This could be thought of as 
referring to glucose concentrations, either pre or post-operatively, or they may refer to 
glycated haemoglobin (HbA1c) concentrations. For many (non-specialist) authors this 
seems to be a relatively minor distinction. However, with the recommendation that the 
group made – that HbA1c concentrations should be less than 69mmol/mol (8.5%) prior to 
elective surgery (where it could be safely achieved) – it was felt important to look at the 
differences in the outcomes if glucose were considered, or if HbA1c was considered when 
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looking at post-operative outcomes. Thus this systematic review emerged looking at all of 
the data that had been published in a large number of surgical specialities where HbA1c 
concentrations had been measured and outcomes assessed. 
 
Objectives of the study 
Using a systematic review of published work, to assess the relationship between long-term 
preoperative glycaemic control (as measured by HbA1c) and risk of developing 
postoperative complications.  
 
What this study added to the literature 
This was the first time that such a systematic review had been carried out, and although 
the results were not in keeping with the findings of high glucose concentrations – i.e. that 
high pre-operative HbA1c concentrations were associated with poorer outcomes – the 
authors came to the conclusion that the reason they did not see this was because the 
studies included were relatively heterogeneous, predominantly retrospective, and often 
contained small patient numbers. Thus it was difficult to make any firm recommendations.  
 
 What changed as a result of the paper? 
The JBDS guidelines still recommend that for elective surgical patients, HbA1c should be 
<69mmol/mol (8.5%) where it can be safely achieved. This is broadly in line with 
observational data from a large single centre cohort from the USA who showed that post-
operative harm was much more likely to occur is HbA1c values were >64mmol/mol (8.0%) 
[173]. I am aware that with the Association of Anaesthetists of Great Britain and Ireland 
and the Royal College of Anaesthetists becoming more aware of the importance of peri -
operative glycaemic control, that the findings of the systematic review, far from making 
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them less enthusiastic about controlled peri-operative HbA1c and glucose concentrations 
has made them more determined to collect the evidence using larger studies. 
 
In retrospect, what should have been done differently in this study? 
This was a systematic review, and thus the authors were entirely reliant on collecting the 
published literature, which was done very methodically. Thus they review process, which 
followed the PRISMA checklist [174].  
 
Future work as a result of this publication 
As mentioned elsewhere in this thesis, work is currently in progress to set up a large multi-
centre study recruiting 15,350 people due to undergo surgery to assess the relationship 
between pre-operative glucose and HbA1c concentrations and 30 day post-operative 
outcomes. This proposed study will help to answer the question set by the systematic 
review. 
 
Confirmation of authorship 
This is shown. 
 
External link to the paper on the journal website 
http://www.clinicalnutritionjournal.com/article/S0261-5614(15)00082-5/pdf   
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Summary and Conclusions  
I started this thesis by stating my hypothesis: That because of the work I have published, 
the management of in-patients with diabetes has improved. Whilst I can offer no absolute 
‘proof’ that my contributions have directly helped improve the care of people in hospital 
with diabetes, there are other direct markers of care that may help to make this inference.  
 
Firstly, there are the data from the most recent most recent (2016) National Diabetes In-
patient Audit that showed several areas where, over the last few years, care has changed 
– often improving, but not always. 
 
Since 2010, the National Diabetes In-patient Audit has tracked the care of hospital in-
patients with diabetes. The data from the 2016 audit carried out amongst 209 hospital 
sites across the UK was that the prevalence of diabetes amongst in-patients continued to 
rise and was, on average, 17%, this figure has risen from 15% in 2011 [2]. Several other 
statistics were of direct interest to this thesis: 
 
Hospital stay: 
The 2011 NaDIA showed that only 58% of in-patients were seen by a member of the 
diabetes team. This had risen to 69% in 2016. Unfortunately, 28% of hospitals still do not 
have in-patient diabetes specialist nurses. These two statements are relevant because of 
the data published, and presented in this thesis looking at the impact of the DISN  
 
Hypoglycaemia: 
The prevalence of all hypoglycaemic episodes decreased from 26% in 2011 to 20% in 
2016. Looking more closely, the rates of mild (self-treated) hypoglycaemia fell from 23% in 
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2011 to 18% in 2016, and the rate of severe hypoglycaemia (i.e. requiring third party 
assistance) fell from 11% to 8% between those years. Within the latter category, the 
prevalence of severe hypoglycaemia requiring injectable rescue treatment fell from 2.2% 
in 2011 to 1.7% in 2016. These two statements are relevant because of the guideline 
published, but not presented in this thesis, on the management of hypoglycaemia in 
hospital in-patients [175]. I was a contributor on those guidelines. 
 
DKA and HHS: 
Disappointingly, 4% of in-patients with type 1 diabetes developed DKA during their 
hospital stay, a rise from 3% in 2011. This statement, although very disappointing, is 
relevant because of the work I have done on DKA. Some of this work is presented in this 
thesis. The incidence of HHS in in-patients with type 2 diabetes remained unchanged 
since 2015, at 0.2%. This statement, although very disappointing, is relevant because of 
the guideline published, but not presented in this thesis, on the management of HHS [54]. 
I was a contributor on those guidelines. 
 
Other findings may not have been directly related to the work I have published. These 
include: 
Intravenous insulin: 
The 2016 NaDIA data showed that there were fewer people on intravenous insulin 
infusions – 11% in 2011 and 8% in 2016. In addition, fewer people were on what was felt 
to be excessively long intravenous insulin infusions – 8% in 2011 to 6% in 2016. Finally, it 
was felt by the teams filling out the audit forms that the transfer from intravenous to 
subcutaneous insulin was better, with errors falling from 19% in 2011 to 14% in 2016. 
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These are relevant because there has been a guideline published on this [176]. I was a 
contributor on those guidelines. 
 
Medication errors: 
Despite the increasing use of electronic prescription charts, a proportion of drug charts still 
had at least one medication error. However, the rate decreased from 40% in 2011 to 38% 
in 2016. However this still means that almost two out of five in-patient drug charts had a 
drug error recorded. Drug chart errors were more likely to occur for patients on surgical 
wards – 41% – compared to patients on a medical ward – 37%. Prescription errors were 
less likely to occur if in-patients were treated in a hospital that used an electronic 
prescription chart – 19% – compared to hospitals that did not use have electronic charts – 
25%. 
 
The care of in-patients with diabetes is far from ideal and a lot of work remains to be done. 
I was involved in writing one of the first national training modules for insulin safety, 
however, this was initially free (or made available to individual Trusts at minimal cost) but 
then when the price for these modules rose significantly, alternative training modules were 
developed [177]. I was a reviewer for this new module. Insulin prescribing has a direct 
relationship to this thesis because it addresses patient safety, in particular because insulin 
errors (prescribing, dispensing and administering) have been denoted as ‘Never Events by 
NHS England [122].  
 
In addition, other authors have developed regular staff training on all aspects of diabetes 
care [178]. However, despite some authors putting in a huge amount of work into specific 
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aspects of in-patient diabetes care, it does not always show evidence of improved 
outcomes [133,179,180].  
 
However, to date there has been little incentive for Trusts to become actively involved in 
the management of in-patients with diabetes. The issue has in the past been thought to be 
‘too big’ to appear on Trust management ‘radars’ when dealing with the consequences of 
poorly controlled diabetes, because of the lack of a cohesive way of measuring harm. 
However, this may soon change.  
 
Since 2013 I have been part of a small group of people from the JBDS who have lobbied 
the Care Quality Commission (CQC) to highlight the plight of in-patients with diabetes. 
From many ‘corridor conversations’ I have had in the last few years, it is clear that most 
senior managers are not engaged with the concerns that the diabetes specialist teams 
have regarding the care received by this group of in-patients. One of the very few national 
organisations who have the ‘teeth’ – i.e. the power to sanction and make a case for real 
change within Trusts is the CQC. 
 
Some of the senior JBDS team have been CQC inspectors, and with their help and 
guidance, the JBDS have designed a ‘Brief Guide’ and a series of Key Lines of Enquiry for 
use by CQC inspectors. This is for Acute Trusts and Care Homes. These developments 
make diabetes one of the very few ‘disease specific’ areas upon which Trusts will be 
judged (the others being learning difficulties and dementia). Trusts will need to provide 
CQC inspectors as part of the pre-inspection documentation, their NaDIA data and the 
evidence of a number of things:  
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1. That the Trust participates in the annual national diabetes in-patient audit (NaDIA) 
programme 
2. That the Trust has a credible and overarching written strategy for in-patient 
diabetes care across the entire Trust as part of an approved Trust governance 
framework  
3. That the Trust has a written policy for the safe prescribing and administration of 
insulin, linked to direct or online mandatory training of all staff, with evidence of 
adoption of national guidance on in-patient diabetes care and insulin use, and 
programmes to review improvement in outcomes 
4. That the Trust has a dedicated in-patient diabetes specialist service as one of their 
core services, with routine and planned access to this service for all in-patients with 
diabetes, not just emergency admissions 
5. That the Trust has a foot multidisciplinary team (MDT) for in patients with acute 
diabetic foot problems and /or high risk feet while in-patients 
6. That the Trust has a robust system in place to identify all current in-patients with a 
known diabetes diagnosis, with evidence of a rapid referral system to the specialist 
in-patient diabetes team for those experiencing diabetes management problems 
7. That the Trust collect annually, and review, the in-patient experience of diabetes 
care, and the key issues raised, positive and negative 
 
The CQC is a recognised independent arbiter of quality and should an institution fail to 
meet their exacting standards, then the CQC has the power to ‘name and shame’ but also 
impose sanctions on the failing institution. However, until this is rolled out across the UK 
and has been in place for two-three years with regular NaDIA returns, it will be difficult to 
assess their impact.  
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Further evidence that the work I have contributed to has helped to change the care for in-
patients with diabetes is by looking at the numbers of abstracts presented at regional, 
national and international conferences where the JBDS guidelines in particular form the 
basis for local service evaluations and audits. That this work is being carried out suggests 
that individual diabetes teams see the JBDS audit standards as something to aspire to 
and benchmark themselves against. Not only do many of these abstracts show the scale 
of the problem, but also offer innovative and novel approaches to managing such patients.  
 
An (unpublished) example of this is the work done by the surgical and anaesthetic team in 
Northampton General Hospital, led by Dr Karen Leyden, who audited their peri-operative 
pathway in 2013 and found that 7.1% of their surgical patients had diabetes. They reduced 
the number of people with diabetes on a VRIII from 45% in 2009 to 24% in 2013 – in 95% 
of these cases it was deemed that it was the ‘correct’ strategy. They found that the 
number of people who could be managed by simple manipulation of their diabetes 
medication rose from 55% in 2009 to 76% in 2013, with 94% of patients maintaining a pre-
operative glucose of between 4-12 mmol/L, up from 79% in 2009. They found that prior to 
the introduction of the JBDS peri-operative guideline only 75% of patients had a capillary 
blood glucose concentration measured, and this rose to 89% after it had been introduced. 
These changes resulted in the rate of pre-operative hypoglycaemia (i.e. a blood glucose 
concentration of <4.0 mmol/L) falling from 8% to 1%, and the rate of hyperglycaemia 
(>12.0 mmol/L) falling from 13% to 5%. The use of the most appropriate fluid (0.45% 
NaCl/5% glucose/0.15% KCl) rose from 0% in 2009 to 82% in 2013, and the use of 5% 
dextrose fell from 89% to 4%. This was associated with no overall change in sodium 
concentrations, as opposed to a previous mean drop of 2.0 mmol/L. Thus this single 
184 | P a g e  
 
centre data suggests that making a change using a guideline I helped to write made a 
material difference to the care of hospital in-patients with diabetes. 
 
Change is unlikely to come overnight, but knowing where we are is the start of the journey 
when one knows where one needs to get to. The question remains about whether the 
existence of a guideline makes a difference to the management of individual patients. All 
of the guidelines on which I have been an author or contributor need assessment – to see 
whether they work or not. So far, only one guideline has been surveyed [97,98]. Currently 
at least one other is currently being actively considered for national assessment. As the 
response to the data from the national DKA survey has shown there were several aspects 
of the guideline that diabetes teams felt was very valuable, but the fact that individuals 
were not following the guidelines meant that a significant proportion of patients developed 
hypoglycaemia and/or hypokalaemia. Thus more attention needs to be paid to staff 
education in order to ensure that people use the guideline correctly. 
 
Thus there are some positive aspects to a management guideline [181]. Ideally they 
improve the quality of patient care and outcomes. In addition, they unify diagnostic criteria; 
reduce variations in care – discouraging the use of ineffective, dangerous, wasteful or out 
of date models of care; and they allow for retrospective and prospective audit of 
outcomes. They also improve clinical decision making by recommending specific care 
processes. However, they also may prevent the teams using them from seeing other 
points of view or critically appraise their need, or their utility. Indeed, a recent critique of 
the American Diabetes Association guideline on the management of DKA does just that 
[94]. Most importantly, the teams for whom the guidelines are based at should know that 
they exist, should like what they contain, have no barriers to their implementation, use 
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them when appropriate and follow their recommendations. These last requirements are, of 
course, the areas of guideline use that are most prone to being misused. However, as the 
guidelines are used more commonly, one hopes that their use becomes more embedded 
as routine in hospitals that treat in-patients with diabetes. 
 
The prevalence of diabetes continues to rise unabated, and the consequence will be that 
more people with diabetes will be admitted to hospital – for the most part not because of 
diabetes, but they will have diabetes in addition to the condition that necessitated 
admission. As I have tried to describe throughout this thesis, patients with diabetes in 
hospital unfortunately come to greater harm than those without diabetes. However I hope 
that the work that I have done, or contributed to, has in some way mitigated these harms. 
Furthermore, that unifying practice across the UK and elsewhere, has improved the care 
for people in hospital with diabetes and that it will continue to improve from now on.   
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